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Abstract  
Although remarkable decrease in the number of HIV related morbidity and mortality was 
recorded since the start of ART, exploring the effects of different factors determining 
survival of patients plays principal role So as to enhance ART. In such cases, survival 
analysis is the most appropriate method and its parametric version yields more powerful 
estimates than Cox PH provided that, distributional assumptions satisfied. Hence, the 
performances of Cox PH model and different parametric Models in both metric (PH and 
AFT) were compared on 3042 eligible subjects followed for at least six years using 
secondary data obtained from University of Gondar Hospital, ART database. Model 
specific stepwise variable selection procedures were performed on 11 Covariates that 
appeared to be significant by Non-Parametric and independent analysis to fit models with 
the corresponding set of covariates resulting possibly minimum loss of information. 
Based on the statistical information criteria, the Generalized Gamma AFT Model 
provided best fit to the dataset as compared to Cox PH, Exponential, Weibull, Gompertz, 
Log-Logistic and Log-Normal Models. Accordingly, advanced WHO clinical stages (III 
and IV), lower CD4 percent (12-15%), TB co-infection, being bedridden or ambulatory 
functional status, being relatively old in age, having relatively lower weight, the presence 
of Opportunistic Infections and Risky Behaviors were strongly related to relatively 
minimum median survival time (accelerated death time) under the Generalized Gamma 
AFT Model. Gender, Household Size and Educational Level were not selected to fit final 
Generalized Gamma AFT Model, although they were significant by independent analysis 
unlike Occupational Status, Marital Status and Cotrimoxazol that were insignificant at 
all. Statistical software, SPSS and STATA were used for analysis. 
Key Terms: ART, Model Specific Stepwise Procedures, Generalized Gamma AFT 
Model. 
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1. Introduction  
1.1. Background   
The human immunodeficiency virus (HIV) has created an enormous worldwide challenge 
since its recognition. According to [71], it has been possible to know that in 2013 there 
were an estimated 35 million people living with HIV in the entire globe [26]. It had also 
shortened the lives of many others for at least three decades without cure. This pandemic 
is spreading around the globe. It is the reason for many children being orphaned. Since 
the start of the epidemic, 39 million people have died of AIDS related illness [71]. 
Globally, an estimated 2.1 million people were newly infected with HIV in 2013. This 
estimate appeared to be an indication of continues fall in the number of new HIV 
infections in the world because it was the lowest number of annual new infections since 
the mid-to-late 1990s, when approximately 3.5 million people were acquiring HIV every 
year [68]. The drop in new HIV infections was most pronounced among children. From 
2001 to 2013 the number of children newly infected with HIV dropped by 58% [71]. 
Although decrease in number of new infection with HIV is remarkable event, HIV/AIDS 
still has devastating effect on lives of mankind. Considering this large number of loss in 
life due to HIV/AIDS, a lot has been done to reduce HIV/AIDS related mortality and 
morbidity. Now days, this contributed effort brought ART program which has been hope 
for survival of HIV infected patients since its announcement. On the other hand, high 
costs associated with treatments were reasons for losing hope to wards the treatments for 
HIV/AIDS right after the announcement of ARV drug combinations. Despite, it was 
believed to be better way of prolonging the life span of HIV infected patients. 
Fortunately, such problems seem to be solved at this time as the pandemic has gained 
global concern [72]. 
According to [71], the highest proportion of people living with HIV is saturated in sub- 
Saharan Africa. The estimated total number of people living with HIV in sub-Saharan 
Africa by the year 2013 was 24.7 million. It is also reported that a minimum of 1.4 
million people were newly infected with HIV in 2012 and an estimated 1.1 million sub- 
Saharan people experienced HIV/AIDS related death in 2013 [66]. However, new HIV 
infection was declined by 33% between 2005 and 2013 [15]. 
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Ethiopia is one of sub- Saharan Africa countries in which an interval estimate of 
[690,000- 840,000] people were living with HIV since 2012 [42], [72]. Since the first 
evidence of HIV was detected in Ethiopia in 1984 [69], AIDS has claimed the lives of 
millions and left behind hundreds of thousands of orphans [21], [22]. It has also reported 
that there were 14,000 to 29,000 new HIV infections and an interval estimate of [40,000-
56,000] AIDS related deaths [72].   
In 2003, the government of Ethiopia introduced ART program to reduce HIV related 
morbidity and mortality, improve the quality of life of people living with HIV and 
mitigate some of the impacts of the epidemic [28],[29]. Again in 2005, Ethiopia launched 
free ART: over 71,000 were initiated on ART by the end of November 2006 and as of 
March 2010, 511 health facilities (142 hospitals and 369 health centers) provide ART 
service throughout the country to increase access by taking service closer to more people 
recording transport and related costs for patients and families, resulting in improving 
adherence and enrollment in care and treatment services easily in the course of the 
disease [44], [73]. 
In order to achieve the goals of ART, it is better to study different socio-economic, 
demographic and health factors that are expected to have significant effect on the survival 
of HIV infected patients. Besides investigating ways of prevention of the virus before a 
person is HIV positive, it is also of recent interest in medical researches related to 
HIV/AIDS to identify marker events such as time to death, and determining factors 
affecting the length of survival time among HIV infected patients under ART follow-up. 
Due to the presence of various determinants of time to death or survival time, there is a 
great deviation in time to death of HIV infected patients under ART follow-up. 
According to different studies, the survival time of HIV patients under ART follow-up is 
known to be influenced by socio-economic, demographic, and health factors. 
Although different statistical methodologies can be considered to identify such influential 
factors on survival of individuals particularly, HIV patients under ART follow-up, 
survival analysis is more preferable method of statistical analysis to determine factors 
influencing life time of individual patients since time to death can be categorized as ‗time 
to event‘ data[45]. In this particular thesis, individual survival times before experiencing 
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death outcome are defined as the length of time from ART start date until the date of 
death (or censor) measured in months.  
By definition, Survival analysis is a phrase used to describe the analysis of data in the 
form of times from a well-defined time origin until the occurrence of some particular 
event or end point [10]. Hence, survival analysis is also referred to as "time-to-event 
analysis", which is applied in a number of applied fields, such as medicine, public health, 
social science, and engineering [34].  
On the basis of assumptions, Non- parametric, semi- parametric and parametric methods 
are classification of statistical methods used to analyze a survival data. Non-parametric 
methods work well for homogeneous samples; they do not determine whether or not 
certain variables are related to the survival times [45]. This leads to the application of 
regression methods for analyzing survival data. The standard multiple linear regression 
models are not well suited to survival data for several reasons. First, survival times are 
rarely normally distributed. Second, censored data result in missing values for the 
dependent variable [45]. 
In survival analysis studies, a descriptive summary of characterizing the different survival 
distributions that correspond to different subgroups within a heterogeneous population 
could consist of parametric or semi parametric methods. There are two major regression 
models used for survival data: proportional hazards model (Cox) as a semi parametric 
method and accelerated failure time model or linear model representation in log time as a 
parametric model [45]. 
Cox proportional hazard model assumes that the underlying hazard rate is a function of 
the independent covariates, but no assumptions are made about the nature or shape of the 
baseline hazard function. That is why Cox‘s model is referred to as a semi-parametric 
model for the hazard function. This model keeps the baseline hazard as an arbitrary, 
unspecified, and nonnegative function of time. It is the most popular and commonly used 
model by researchers in medical sciences mainly because of its simplicity, and not being 
based on any assumptions about the survival distribution [16]. However, Cox PH model 
has the restriction that proportional hazards assumption holds with time-fixed covariates; 
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and it may not be appropriate in many situations and other modifications such as 
stratified Cox model or Cox model with time-dependent variables are required [40].  
The Accelerated Failure Time (AFT) model is another alternative method for the analysis 
of survival data. Although the Cox regression model is the most favorable employed 
technique in survival analysis, parametric models do have a number of benefits [45]. 
The details on different survival data analysis methods are presented on the 3
rd
 chapter of 
this thesis. However, the main purpose of this study is to support an argument that AFT 
models can be used as best alternative to Cox PH models to determine factors that 
significantly affect the survival time of HIV patients. 
1.2. Statement of the Problem 
Although a lot of enquiries have been conducted in different hospitals of Ethiopia in 
investigating factors affecting the survival time of HIV infected patients under ART 
follow-up, there are inconsistencies in results of different studies which leaded to 
contradicting conclusions about the effect of some factors on survival times of patients. 
Specifically, age, gender and educational level are some of the factors that the same 
conclusions couldn‘t be given by different researchers regarding their effect on survival 
time of HIV patients under ART follow-up. Hence, degree of uncertainty associated with 
the effect of such factors needed to be minimized. 
Moreover, almost all of the studies were conducted on patients of age between 15 and 75 
years for which the maximum follow-up time was not more than 5 years. So that, 
conclusions can‘t be made for patients of age other than between 15 and 75. In addition 
to this, results of such studies may be affected by high proportion of censored 
observations due to relatively shorter follow-up time since death from HIV/AIDS take a 
decade on average unless patients die from other cases. Basically, it is now becoming 
many years since ART has been launched in Ethiopia. As a result, the time at which the 
studies have been conducted also has effect on the length of follow-up time because 
recently conducted studies could have relatively long follow-up time to consider than 
those had been conducted before. Number of observed survival times were considered in 
sample size determination rather than number of death events in some of the studies. 
Therefore, it was not only the length of follow-up time, but also the mechanism by which 
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samples have been taken was one of the main causes to have high proportion of censored 
survival times. 
Essentially, appropriate method of statistical data analysis should be used to get accurate 
results. Some of the studies conducted so far used logistic framework. However, for time 
-to -event data, survival analysis method is more powerful than the logistic framework as 
it takes censuring into consideration while the probit analysis (logistic framework) 
restricted attention to the events that occur within the shortest observed follow-up time 
that leads to a huge waste of information. 
Most importantly, the absence of studies conducted to compare parametric (AFT) with 
Cox PH methods of survival analysis on the basis of determining most significant factors 
affecting the length of life time of patients under ART follow-up especially in Ethiopia 
motivated this study since parametric methods of statistical analysis is more powerful 
than non-parametric and semi-parametric method of analysis provided that distributional 
assumptions are satisfied. Moreover, comparisons made before on datasets other than 
ART were performed on the basis of the same sets of covariates regardless of model 
specific stepwise procedures.  
In this context, the following questions are addressed:- 
 Does Cox PH model provides better fit to time-to-death HIV data than parametric 
survival (AFT) model in this particular study? 
 Which socio-economic, demographic and health factors have statistically significant 
effect on survival time of HIV infected patients? 
 Which factors/categories are associated with shorter survival time of HIV patient? 
 Which factors/categories are associated with prolonged survival time of patients? 
1.3. Objectives of the Study 
1.3.1. General Objective 
The general objective of this study is to identify statistically significant determinants of 
time to death event of HIV infected patients under ART follow-up in Gondar hospital, 
Ethiopia. 
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1.3.2. Specific Objectives 
 To identify factors that affects the survival time of HIV/AIDS patients under ART 
follow-up. 
 To assess performance of Cox PH model relative to parametric (AFT) models 
based on a given particular dataset.  
 To formulate a model that results in statistically plausible and interpretable 
estimates of the effect of important determinants of survival time for ART data. 
1.4. Significance of the Study 
 The outcome of this study may help concerned health policy makers to plan and 
design effective strategies and policies which can undertake children in to 
consideration to minimize HIV related mortality. 
 It minimizes degree of uncertainty on the effect of some factors on survival time 
of HIV patients. 
 It helps to identify the most important determinants of death among HIV infected 
patients so that appropriate possible interventions could be made by clinicians on 
an intent to control factors related to accelerated death time HIV/AIDS patients. 
 It helps to examine the nature of correlation/association between survival time 
and different socio-economic, demographic and health factors by using both semi-
parametric and parametric methods of survival analysis. 
 It gives basic clue about fitting the different alternatives of modeling time to event 
data in survival analysis. 
 It helps to investigate the impact of TB on HIV patients. 
 It paves way for researchers to conduct further enquiry as it can contribute for 
growing literatures on statistical analysis particularly, on modeling time to event 
data; survival analysis.  
1.5. Demarcation of the Study 
1.5.1. Scope of the Study 
The major concern of this study is determining the most important statistically significant 
socio-economic, demographic and health factors that can affect the life span of 
HIV/AIDS patients. It also categorize factors/factor levels to differentiate among which 
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categories of factors are associated with accelerated death time and which of them belong 
to prolonging life time of HIV infected patients. 
Besides identifying those factors, both parametric and semi-parametric survival analysis 
methods are used in modeling death time of HIV/ AIDS patients on intent to support the 
argument that AFT models can be used as alternatives to Cox PH in modeling time to 
event data. In this regard, modeling time to event is modeling time to death of HIV 
infected patients under ART follow-up in Gondar hospital, Ethiopia. More over this, the 
non-parametric methods of survival analysis are used to describe the median survival 
time of patients. Cox PH and the best fitted AFT model(s) are also checked for 
assumptions.  
All age groups are considered for this study including children. After determining eligible 
subjects for retrospective cohort of study, subjects were followed for at least six years 
right after the initiation of ART to experience death from any case or being censored. 
1.5.2. Limitations  
 The study presumed that all deaths were caused by HIV/AIDS. 
 Parts of information on some individuals was missed due to the presence of drop 
out, transfer out, withdrawal or lost to follow-up.  
 All attributes required for this study were not recorded either because of transfer 
in from other ART clinic or poor data base management system. 
 Poor data searching system on different patient charts to identify event time. 
 The study was based on baseline values of the variables of interest. 
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2. Review of Related Literatures 
2.1. Theoretical Literature Review 
2.1.1. Overview of HIV and AIDS 
Although we often hear the terms ―HIV‖ and ―AIDS‖ used interchangeably, HIV and 
AIDS are not the same things. The abbreviation HIV stands for Human 
Immunodeficiency Virus. HIV is the virus that causes Acquired Immune Deficiency 
Syndrome, otherwise known as AIDS. AIDS develops in the late stages of HIV infection 
[38]. 
A person who has been infected with HIV is referred to as being HIV positive (HIV+). 
An HIV+ person may be asymptomatic, meaning that he may not have any symptoms of 
being infected. Although there are many negative stereotypes of HIV-infected people, it 
is impossible to look at someone and tell if he is HIV+. Many people who are infected 
with HIV may look and feel healthy [59]. Just because a person has been infected with 
HIV does not mean that he has or will be certain to develop AIDS. However, left 
untreated, most people with HIV infection eventually do develop AIDS. Without 
treatment, the time frame between a person becoming infected with HIV and 
subsequently developing AIDS is generally eight to ten years. However, there are cases 
of HIV+ people remaining asymptomatic for over two decades [38]. 
As noted, AIDS is an acronym for acquired immune deficiency syndrome. This is a 
condition that develops from HIV infection. The full name is an accurate description of 
what occurs to a body infected with HIV; namely, it results in a deficient immune system 
[38]. 
As most people know, our immune system is the body‘s collective attempt to fight off 
whatever may be compromising healthy bodily functioning (bacteria, viruses, etc.). It is 
activated when we become ill or have the potential to become ill. For healthy people, it 
permits timely recovery and healing from illness. When compromised, it results in a 
reduced ability to fight off infection and increases the likelihood of becoming ill with 
other diseases. These infections are called ―opportunistic‖ because they take the 
opportunity to attack when immune systems are immunosuppressed, meaning the 
immune system is functioning too poorly to fight off the infection. Although we 
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commonly hear and use the terminology of someone ―dying of AIDS,‖ people actually do 
not die of AIDS. What they do die of are these opportunistic infections that overwhelm 
their bodies [38]. 
2.1.2. Origin of the Virus 
The earliest known case of HIV infection was discovered in a blood sample drawn in 
1959 from a man in Kinshasa, Democratic Republic of Congo (formerly Zaire). Although 
many theories about the origin of AIDS ranging from government conspiracies to aliens 
have been suggested, many researchers now generally agree that AIDS began somewhere 
in the Central African region. They believe that it likely developed from a simian virus 
that infected chimpanzees and somehow managed to cross over into humans, mutating 
into HIV perhaps in the 1930s. That could have happened when people ate the meat of, or 
were bitten by, the infected animals. Due to the geographic isolation of the area, the virus 
likely traveled out of the region slowly, eventually establishing itself in human hosts who 
spread the virus unaware of its existence [38]. 
2.1.3. Transmission of HIV 
Like all other epidemic and pandemic diseases throughout history, when AIDS was 
identified, there was a great amount of fear about how it could be transmitted. 
Particularly early in the AIDS crisis, before any AIDS medications were available and at 
which time AIDS was considered always fatal, fears were especially profound. Social 
stigmas such as the prevalence of HIV/AIDS among marginalized groups such as gay 
men and intravenous drug users compounded the fears and resulted in discrimination. In 
some cases, people were so afraid that their behavior toward people who were infected 
with or even suspected to have HIV even became violent [38]. 
Researchers have now concluded that HIV is not an airborne virus like the influenza virus 
that means, someone cannot get infected with HIV, for example, by conversing with or 
sitting near someone in an airplane or theater who is HIV+. Fortunately, HIV is not a 
very robust virus when outside of the body. This means that it deteriorates fairly rapidly 
when not in an ideal environment like the body provides. It is neither able to replicate nor 
reproduce outside of the body, and any fluid that is infected with HIV that dries due to 
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exposure to the outside environment effectively renders HIV dead. This is why the 
likelihood of contracting HIV from casual environmental contact is remote [38]. 
HIV is not transmitted by insects such as fleas (as was the case in the plagues that swept 
through the world during the medieval period), and it is not transmitted by mosquitoes (as 
is malaria or the West Nile Virus). Additionally, HIV is not transmitted by touching, 
hugging, or shaking hands with an infected person [38]. 
HIV is transmitted through four body fluids: blood; semen; vaginal secretions; and breast 
milk. As such, prevention efforts have been, and continue to be, focused on limiting or 
eliminating the possibility of individuals transferring these fluids between one other. This 
is why there have been such well known public campaigns for safe (or safer) sexual 
practices, syringe exchange programs, and HIV testing for pregnant women; these 
campaigns have targeted the primary means of HIV transmission as a collective effort to 
reduce the likelihood of transmission [38]. 
Other unusual cases of HIV transmission have been documented, but upon investigation, 
all have involved some exchange of one of these infected body fluids [64]. For example, 
in a rare case of transmission by deep kissing, both people had bleeding gum disease [8]. 
In other rare cases in which transmission occurred from adult to child from HIV+ adults 
pre-chewing food for infants, the adults also had bleeding gum disease and fed teething 
children [27]. 
2.1.4. How Does HIV Work? 
Recall that HIV is the acronym for the human immunodeficiency virus. Notice that the 
final word in this sentence is virus; this is precisely what HIV is, a virus. Viruses are 
microscopic biological agents that are technically not considered to be living, as they do 
not meet the scientific requirements for what constitutes life (e.g., able to grow and 
reproduce, adapt to environmental conditions, etc.) They are only able to replicate and 
reproduce themselves through the use of other cells. Specifically, they attach (infect) 
themselves to a host cell and deliver their genetic material to the cell. They then hijack 
the cell‘s mechanisms for reproduction and use the cell to replicate many versions of 
themselves. Eventually, the cell becomes full of the replicated viruses and its structure 
begins to fail. The volume of replicated viruses in the cell causes the cell to burst, 
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destroying the cell and releasing the replicated viruses to infect other cells. In this 
manner, the viruses spread to other cells replicating themselves, and in the process they 
destroy all of the cells used as replication centers [38]. 
HIV attaches to two types of white blood cells: T cells and CD4 cells. These cells are 
components of the human immune system, and their cellular health is vital to the health 
of the immune system. When HIV attaches to T-cells and uses them as hosts to create 
more copies of it, it destroys them in the process. Destruction of T-cells results in a 
critically impaired immune system; this, then is what leads to the condition known as 
AIDS [38]. 
The Human Immunodeficiency Virus (HIV), a retrovirus, was identified in 1983 as the 
etiologic agent for the Acquired Immunodeficiency Syndrome (AIDS). AIDS is 
characterized by changes in the population of T-cell lymphocytes that play a key role in 
the immune defense system. In the infected individual, the virus causes a depletion of 
subpopulation of T-cells, called T-helper cells, which leaves these patients susceptible to 
opportunistic infections as well as certain malignancies [8], [47]. 
So, HIV is simply the virus with which one gets infected. Preventing AIDS requires 
preventing HIV infection. This is why it is important to understand how HIV is 
contracted, how it spreads, who is most at risk, what kinds of prevention practices can be 
put in place, etc. If HIV is prevented, the development of AIDS is prevented [38]. 
As noted above, unlike infection from other viruses that result in changes in homeostasis 
in the body, infection with HIV does not immediately result in symptoms like chills, 
fever, aches, and pains, etc. Persons infected with HIV can live symptom free for many 
years; in fact, it is estimated that 25% of people infected with HIV are unaware of being 
infected. The only way to know if someone is infected is to get tested. This is why there 
has been an effort for the past 25 years for people to get tested for HIV [38]. 
2.1.5. Developing Drugs to Treat HIV 
Before HIV was isolated as the virus that causes AIDS, doctors were at a loss for 
effective ways to help their patients. They treated the opportunistic infections, but could 
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do nothing about addressing the cause of AIDS, so AIDS was widely considered a death 
sentence. Desperate patients grasped at desperate measures [38]. 
Earlier researchers looking for a drug to combat HIV focused on experiments using 
known antiviral medications. These drugs generally did little to benefit patients; some 
had uncomfortable of even dangerous side effects, but they were the only hope many 
people with HIV and their loved ones had. When Ribavirin, an established drug used for 
viral respiratory disease, showed some potential in slowing the onset of AIDS, AIDS 
patients illegally imported it from Mexico before being able to obtain it use against AIDS 
in the United States [20]. 
The first anti-HIV drug approved by the FDA as effective in fighting AIDS was 
azidothymidine, commonly known as AZT, and sold as Retrovir. It was approved for use 
by the FDA on March 19, 1987. Although the breakthrough in treatment was exciting, 
AZT therapy was cumbersome. It required some 12 pills per day, taken two at a time 
every four hours around the clock [63]. It was also extremely expensive: $3.00 per pill, or 
$8,000–$10,000 for a typical year‘s supply of medication. Public pressure eventually led 
to decreased costs. Even so, the drug was extremely profitable for the manufacturer, 
earning more than $300 million annually by 1994 [20], [60]. Even the WHO in a 1994 
meeting declined to endorse AZT for use around the globe for pregnant women due to 
costs and access issues, recommending a solution of ―simpler and less costly‖ therapies 
be developed [60]. AZT was also proved to have uncomfortable and even dangerous side 
effects as well (e.g., nausea, vomiting, headaches, fatigue, anemia, muscle pain and 
weakness, and neutropenia a low white blood cell count that increases susceptibility to 
infection) to the extent that some patients stopped taking the drug. 
Researchers raced to develop new drugs to fight HIV, yet the virus was proved to be a 
formidable adversary. Researchers discovered that problems arose with so-called mono 
therapy treating HIV with only one drug. When attacked with only one drug at a time, 
HIV mutated and became resistant to that drug. The resistant strains of HIV could then be 
passed on to others [38].  
As this problem became increasingly apparent to researchers and newer drugs became 
available, standard therapy for HIV starting in the mid-to-late 1990s became combination 
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therapies that used various drugs together to combat HIV. Highly Active Anti-Retroviral 
Therapy, known by the acronym HAART, uses combinations of three or more drugs to 
reduce the chance of HIV drug resistance. Doctor David Ho of New York City‘s Aaron 
Diamond AIDS Research Center was recognized as Time magazine‘s Person of the Year 
for 1996 for his pioneering work on combination therapies [9], [20]. However, problems 
with side effects, patient adherence to difficult medication schedules (some requiring 30 
pills to be taken throughout the day with varying dietary requirements), and high drug 
costs persisted [20]. By 2008, over 25 different combinations of medications had been 
developed as ―second line‖ therapies and even as ―salvage‖ therapies to fight these drug 
resistant strains. One pill a day therapies multidrug combination products have also been 
developed to try to overcome some of the ongoing problems of resistance, side-effects, 
and cumbersome medication schedules [18], [24], and [64]. 
Pharmaceutical development is a lengthy and expensive process involving a number of 
stages. In the early stages, the drug is developed and tested in a laboratory and on 
animals. If the drug is determined to be safe and produces promising results, it goes 
through a process requiring three more phases of testing on human volunteers. The next 
phases are called clinical trials. These phases take several years (for example, more than 
two years for the first phase and up to four for the third phase) and include larger 
numbers of people for testing at each stage of the process, ranging from 10 to 100 
volunteers in Phase I, to several hundred in Phase II, to several thousand in Phase III. 
Researchers progressively build data on the safety, effectiveness, dosage, and any side 
effects. If the drug proves satisfactory, it may be licensed and become available for 
widespread use [23], [37], [62], and [46]. Due to activism by HIV/AIDS advocacy 
groups, this process has actually been speeded up for HIV drugs. 
2.2. Empirical Literature Review 
2.2.1. Socio-Economic, Demographic and Health Factors Affecting Survival of HIV/AIDS 
Patients under ART Follow-Up 
In this section of literature review, the main focus is to get information about socio-
economic, demographic and health factors that are significant determinants of death time 
among HIV/AIDS patients under ART follow-up from previously conducted related 
studies. Moreover, this literature review also shows that some factors on which 
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contradicting conclusions have been made concerning the significance of their effect on 
survival. 
According to a retrospective cohort study conducted in the Far-North province of 
Cameroon to analyze the outcomes of ART in routine conditions in a rural hospital on 
1187 patients of age greater than 15 years who started ART between July 2001 and 
December 2006, CD4 count, hemoglobin, BMI, sex and clinical stage at enrolment were 
found to be independent predictors of mortality. In this study, the survival time was 
estimated by Kaplan–Meier analysis and Cox proportional hazard models were fitted to 
explain survival. Results Upon enrolment, 90.4% patients were in WHO stage III or IV 
and 56.1% had a BMI<18.5. Median CD4 count was 105 cells⁄mm3 (IQR 40–173). At 
the end of the study period, 338⁄1187 had died and 59⁄1187 were lost to follow-up. The 
survival probability was 77% at 1 year [95% CI: 75–80] and 47% at 5 years [95% CI: 
40–55]. The median survival time was 58 months [31]. 
Similarly, another study was conducted based on data collected during the follow-up time 
from 2005 to 2008 at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. Out of 
a population of HIV patients who were taking antiretroviral therapy in the hospital in that 
period, data on 1,000 patients were used for this study. The study subjects were people in 
the age range from 15 to 75 years. The Kaplan-Meier Method was employed to estimate 
mortality; the Cox Proportional Hazards Regression Method was used to identify 
determinants of mortality. After initiation of the antiretroviral treatment, HIV-positive 
patients lived for an average of 5.65 years (CI:3.69-7.61  years);  the  median  survival  
age  was  found  to  be  3.98  years  (CI:  2.98-4.97 years). The number of medications,  
baseline  functional  status,  CD4  count,  antiretroviral  treatment,  age,  gender  and  
weight  impact  the survival experience of the patients [67]. 
On the other hand, the result of a study conducted in Adama Hospital, Ethiopia showed 
that age and access to running water appeared to have non-significant effect on 
survival/death status. The study evaluates factors affecting the chance of survival/death 
status among HIV positive people under ART follow-up. The socio economic factors 
such as previous HIV counseling, residence, employment status, number of rooms, 
availability of running electricity; demographic and health factors like gender, marital 
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status, educational level, TB status, weight, CD4 count and clinical stage; risk behavior 
factors:-condom use, tobacco alcohols and drug use were factors that had statistical 
significant effect on survival/death status of patients by multiple logistic regression 
model [50]. 
In contrast, according to a study conducted in south Wello, Ethiopia, It has determined 
that, the level  of  marital status, residence, TB status, clinical stage, weight, age, CD4 
level, and lymphocyte count are that manifest differences in survival. But gender and 
education level show no significant effect on survival. In this study, a sample of 654 out 
of 7163 patients of age between 15 and 75 was selected that were followed from 1 
January, 2008 to 31 December, 2011to identify factors related to the survival of 
HIV/AIDS patients under ART follow-up. The result of the study shows that, HIV-
positive patients lived for an average of 41.81 months (CI: 40.61-43.00 months. The 
study employed The Kaplan-Meier estimator (product-limit-estimator) of the survival 
function to compare the survival functions of two or more groups. The log-rank test was 
utilized to test whether observed differences in survival experience between/among the 
groups was significant or not. The semi-parametric regression model known as the 
proportional hazards regression (PHR) model was also used for the analysis [33]. 
Furthermore, Educational level of individual patients appeared to have significant effect 
on survival in a study conducted in armed forces general teaching hospital Addis Ababa, 
Ethiopia. The study revealed that employment status, number of rooms, household size, 
functional status, CD4 cell count, WHO clinical stage, OIs, TB, ART, age and weight of 
the patients were also candidate predictors for further analysis. In this study patients were 
followed up for a median of 38.5 months and the overall mean estimated survival time of 
patients under the study was 72 (95% CI: 70-  74) months. Kaplan-Meier and Nelson 
Aalen estimation techniques were used to get a closer look at estimate of the survival 
time. In order to study the relationship  between  survival  time  and covariates, a 
regression  modeling approach  to  survival  analysis  using  the  Cox  proportional  
hazards  model  was employed [39]. 
In summary, the studies have been conducted to determine different factors that affect 
survival of HIV/AIDS patients under ART follow-up. However, different conclusions 
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have been made on the effect of some factors specifically, age, gender and educational 
level. The follow-up time for most of the studies employed survival analysis was not 
more than 4 years. And hence, analyses were affected by relatively high proportion of 
censored observations. Finally, most of the studies were conducted on specific age group 
of patients (>15 or between15 and 75). As a result, some of the researchers listed it as 
their limitation since results are not applicable for patient population of age excluded 
from the studies.  
2.2.2. Comparing Cox PH versus AFT Survival Analysis Models 
A review of literature on survival analysis used in different journals reveals that the Cox 
PH model is the most widely used way of analyzing survival data in clinical research. 
Researchers in medical sciences often tend to prefer semi-parametric instead of 
parametric models because of fewer assumptions. However, in recent time, AFT models 
as parametric models have attracted considerable attention, because not only they do not 
need PH assumption but also thanks to availability of standard statistical software ML 
parameter estimation and testing can be done readily [2],[45]. 
The main drawback of parametric models is the need to specify the distribution that 
most appropriately mirrors that of the actual survival times [14]. This is an important 
requirement that needs to be verified and an appropriate distribution may be difficult to 
identify. When a suitable distribution can be found, the parametric model is more 
informative than the Cox model. It is straightforward to derive the hazard function and 
to obtain predicted survival times when using a parametric model, which is not the case 
in the Cox framework. Additionally, the appropriate use of these models offers the 
advantage of being slightly more efficient; they yield more precise estimates (i.e. smaller 
standard errors) and that in the parametric models we often use maximum likelihood 
procedures to estimate the unknown parameters in which this technique and its 
interpretation are familiar for researchers [7]. 
The parametric approach offers more in the way of predictions, and the AFT formulation 
allows the derivation of a time ratio, which is arguably more interpretable than a ratio of 
two hazards in Cox PH models. However, AFT models are relatively unfamiliar and 
seen rarely in medical research [45]. 
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To the best of my knowledge, many studies have not been conducted in comparing the 
performance the Cox PH and parametric AFT models using ART HIV/AIDS data to 
determine factors affecting the survival time of HIV/AIDS patients. However, the 
performance of Cox PH and AFT models has been compared in the analysis of HIV/TB 
Co-infection Survival data in Ghana.  In this study, there were 76 patients on treatment 
of HIV/TB Co-infection from the year 2008 to 2013.the Cox model and (Exponential, 
Weibull, Lognormal, Log-logistics and Gamma) as AFT models have been compared 
using HIV/TB Co-infection data.  The result showed that, the Cox model was fitted and 
diagnosed with the proportionality assumption satisfied. The martingale residual 
indicated that the model was linear. Comparing the Cox model with the AFT models 
based on the AIC and BIC showed that the Gamma model had the lowest value. It was 
also observed that weight, CD4 cell count and the Religion were significant 
determinants of the patient‘s survival at 5% significance level. The result revealed that 
the gamma model provided a better fit to the studied data than the Cox proportional 
hazards model [17]. 
Performance comparison between Cox PH and parametric survival models have also 
been made on other data sets other than ART such as survival of patients with different 
disease for example cancer. Accordingly, the analysis of Survival of Patients with 
Gastric Carcinoma of data from a historical cohort study of southern Iran with a 
diagnosis of stomach cancer has been made using Cox PH. and parametric Lognormal, 
Exponential, Gompertz, Weibull, Log logistic and Gamma regression models in which 
all parametric survival models were performed better than the Cox model. In this study 
the proportional assumption is checked and found to be hold, but the model diagnostic 
for the parametric case has not been made yet. The comparison of Parametric and semi 
parametric models was made based on AIC [54].  
According to a study on Infant Feeding Survival and Markov Transition Probabilities 
among Children under Age 6 Months in Uganda, The multivariate analysis of the Cox, 
Weibull, and exponential models yielded similar results. Effect estimates were slightly 
lower in parametric models than in Cox models but were not significantly different for 
any of the parameters. Both the Weibull model and the exponential model had a lower 
Akaike Information Criterion than the Cox model and hence had better fits. A graphical 
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check of the proportional hazards assumption was performed, and the proportional 
hazards assumption did not appear to be violated (not shown). Graphical checks were 
also performed for all models using Cox-Snell residuals to determine model fit. These 
showed that both parametric models were better-fitting than the Cox model [41]. 
Another study conducted on retrospective cohort study of 746 patients with gastric 
cancer in Iran with the aim of comparing the Cox regression model against parametric. 
According to this study a multivariate analysis Cox and Exponential are similar. 
Although it seems that there may not be a single model that is substantially better than 
others, in univariate analysis the data strongly supported the log normal regression 
among parametric models and it can be lead to more precise results as an alternative to 
Cox [53].  
Similarly, a study conducted on prognostic factors of survival time after hematopoietic 
stem cell transplant in acute lymphoblastic leukemia on 206 patients were enrolled after 
HSCH in Shariati Hospital between 1993 and 2007 so that the performance among AFT 
and Cox's models was assessed using explained variation and goodness of fit methods. 
Accordingly, predictive power of Weibull AFT models was superior to Cox PH model. 
Cox-Snell residual shows Weibull AFT fitted to data better than other distributions in 
multivariate analysis [57]. 
In a similar fashion, a study on the survival of 1236 tuberculosis patients admitted in 
randomized controlled clinical trial in India. The result for this study showed that AFT 
model gave smaller deviance showing that AFT models have seem to be more 
appropriate modeling than the Cox PH model [52].  
Furthermore, AFT model was used to analyze data from 16 survivorship experiments in 
aging research experiments that evaluated the effects of one or more genetic 
manipulations on mouse lifespan. According to this study, AFT model deceleration 
factors also provided a more intuitive measure of treatment effect than the hazard ratio, 
and were robust to departures from modeling assumptions [65].  
In contrast, in analysis of survival in acute severe illness, AFT models identified the 
same predictors as the Cox model, but did not demonstrate convincingly superior overall 
fit than the Cox PH model does and the analysis of survivals of breast cancer relapse 
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time with different treatments consistent results were obtained from accelerated failure 
time model and Cox proportional hazard model. But Cox PH is also chosen over 
accelerated failure time model to calculate the appropriate survival curves of relapse 
time for patients in different treatment groups. i.e., With respect to predicting survival 
curve, Cox-PH model gives better fit than AFT models [11]. 
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3. Data and Research Methodology  
3.1. Study Area and Data Source   
In this retrospective cohort study, the information was collected from ART database in 
University of Gondar Referral Hospital. The University of Gondar Referral Hospital  is  
found  in  Gondar  city,  which  is  located  727 km northwest of Addis Ababa. The ART 
service for University of Gondar Referral Hospital was initiated in 2003 and has had 
Adult, Pediatric, and PMTCT clinics [6]. The collected information was secondary data 
type from which necessary attributes have been obtained to identify the most important 
determinants of survival among HIV/AIDS patients under ART follow-up in Gondar 
hospital. 
Intending to achieve the objective of this study leaded to the sampling frame HIV 
positive patients who were found in Gondar hospital under the follow-up of ART. The 
study focused on patients of all age who started ART between 2003 and 2009 that were 
followed until April, 2015 considering all possibly available attributes in the ART 
database. The obtained data was managed and analyzed by using statistical packages such 
as SPSS and STATA after the required information has been reviewed form ART 
database in Gondar hospital. 
3.1.1. Study Variables 
The Response Variable: In this particular study, the response (dependent) variable was 
survival time of HIV/AIDS patients under ART follow-up. The survival time is defined 
to be the length of time measured in month from ART initiation until time of death 
(censor). 
Independent Variables: Predictors (covariates) taken at baseline value which were 
expected to have effect on the survival time of HIV/AIDS patients are listed as follows:- 
 Age in years  
 Sex (Male, Female)  
 Marital status (Never Married, Married, Widowed or Divorced)  
 Baseline Weight (kg)  
 Level of education (Educated, Not Educated)  
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 Risk Behavior (Smoking, Alcohol, etc.) (No, Yes)  
 Baseline CD4 cell Percent (12-15%, 16-28%, Above28%)  
 WHO clinical stage (Stage I, Stage II, Stage III, Stage IV)  
 Functional Status (Working, Ambulatory, Bedridden)  
 Occupational status (Employed, Unemployed) 
 Opportunistic infections (No, Yes) 
 TB Status (Negative, Positive) 
 Household size (Number of individuals per house) 
3.2. Methods of Data Analysis 
The methodology in this thesis has been built in such a way that non-parametric, semi-
parametric and parametric methods of survival analysis could be applied to ART data on 
intent to compare the performance of Cox PH and AFT models in determining significant 
factors that affect survival time of HIV infected patients.  
3.2.1. Introduction to Survival Analysis 
Survival analysis is the phrase used to describe the analysis of data in the form of times 
from a well-defined time origin until the occurrence of some particular event or end 
point. Typically, Survival Analysis focuses on time to event data. In the most general 
sense, it consists of techniques for positive valued random variables [19]. In medical 
research, the origins will often correspond to the recruitment of an individual into an 
experimental study, such as clinical trial to compare two or more treatments. This in turn 
may coincide with the diagnosis of a particular condition, the commencement of a 
treatment regimen, or the occurrence of some adverse event. If the end point is the death 
of a patient, the resulting data are literally survival times. However, data of similar form 
can be obtained when the end point is not fatal, such as the relief of pain, or the 
reoccurrence of symptoms.in this case, the observations are often referred to as time to 
event data [10],[32].    
The problem of analyzing time-to-event data arises in several applied fields such as 
medicine, biology, public health, epidemiology, engineering, economics, sociology, 
demography and etc. The terms lifetime analysis, duration analysis, event-history 
analysis, failure-time analysis, reliability analysis, and transition analysis refer essentially 
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to the same group of techniques  although  the  emphases  in  certain  modeling  aspects  
could  differ  across disciplines [1], [51].  
The main feature of survival data that renders standard methods inappropriate is that 
survival times are frequently censored [25]. The survival time of an individual is said to 
be censored when the end point of interest has not been observed for that individual. This 
may be because the data from a study are to be analyzed at a point in time when some 
individuals are still alive [55]. Alternatively, the survival status of an individual at the 
time of the analysis might not be known because that individual has been lost to follow-
up [10]. 
There are three types of censoring in survival analysis 
A. Right Censoring: A patient who entered at a study time t0 dies at time tt 0 . 
However, t is unknown, either because the individual is still alive or because he/she 
has been lost to follow up. If the individual was last known to be alive at time ct 0 , 
the time c is called a censored survival time. This censoring occurs after the 
individual has been entered in to a study. That is, to the right of last known survival 
time, and is therefore known as right censoring. The right censored survival time is 
then less than the actual, but unknown, survival time. This type of censoring is most 
commonly encountered in survival analysis and hence the term "censoring" will be 
used in this study to mean in all instances "right censoring". 
B. Left Censoring: Another form of censoring is left censoring, which is encountered 
when the actual survival time of an individual is less than that observed. In other 
words, Survival time is said to be left censored if an individual develops an event of 
interest prior to the beginning of the study; left censoring occurs far less commonly 
than right censoring. 
C. Interval Censoring: Here, individuals are known to have experienced an event with 
in an interval of time. That means, Survival time is said to be interval censored when 
it is only known that the event of interest occurs within an interval of time but the 
exact time of its occurrence is not known. 
An important assumption for methods presented in this thesis for the analysis of censored 
survival data is that the individuals who are censored are at the same risk of subsequent 
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failure as those who are still alive and uncensored. i.e., a subject whose survival time is 
censored at time C must be representative of all other individuals who have survived to 
that time. If this is the case, the censoring process is called non-informative. Statistically, 
if the censoring process is independent of the survival time, then we will have non-
informative censoring. Independence censoring is a special case of non-informative 
censoring. In this thesis, we assume that the censoring is non-informative right censoring. 
3.2.2. Survivor Function and Hazard Function 
In summarizing survival data there are two functions of central interest namely, survivor 
function and hazard function. In this section, definitions are given according to [10]. 
The actual survival time of an individual, t, can be regarded as the value of a variable, T, 
which can take any non-negative value. The different values that T can take have a 
probability distribution, and we call T the random variable associated with the survival 
time. Now suppose that the random variable T has a probability distribution with 
underlying probability density function  tf . The distribution function of T is then given 
by 
     
t
duuftTPtF
0
,  
And represent that the probability that the survival time is less than some value t. the 
survivor function,  tS , is defined to be the probability that the survival time is greater 
than or equal to t, and so  
     .1 tFtTPtS                                                                                                 [3.1] 
The survivor function can therefore be used to represent the probability that an individual 
survives from the time origin to some, time beyond t.  
The hazard function is widely used to express the risk of hazard of death at some time t, 
and is obtained from the probability that an individual dies at time t, conditional on 
he/she having survived to that time [43]. For a formal definition of the hazard function, 
consider the probability that the random variable associated with an individual‘s survival 
time, T, lies between t and tt  , conditional on T being greater than or equal to t, written
 tTttTtP  | . This conditional probability is then expressed as a probability per 
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unit time by dividing by the time interval, t , to give rate. The hazard function,  th , is 
then the limiting value of this quantity, as t tends to zero, so that
 
 





 

 t
tTttTtP
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t 


|
lim
0
                                                                               [3.2] 
The function )(th is also referred to as the hazard rate, the instantaneous death rate, the 
intensity rate, or force of mortality. From equation [3.2],   tth  is the approximate 
probability that an individual dies in interval  ttt , , conditional on that person having 
survived to time t.  
Again, from the definition of the hazard function in equation [3.2], we can obtain some 
useful relationships between the survivor and hazard functions. The conditional 
probability in the definition of the hazard function in equation [3.2] is 
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Where  tF   is the distribution function of T. Then,  
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Now, 
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lim is the definition of the derivative of  tF with respect to t, 
which is  tf and so  
 
 
 tS
tf
th                                                                                                                       [3.3] 
It then follows that 
    tS
dt
d
th log ,                                                                                                      [3.4] 
And so,      
    tHtS  exp ,                                                                                                         [3.5] 
Where    
t
duuhtH
0
                                                                                                   [3.6] 
The function  tH  defined in equation [3.6] features widely in survival analysis, and is 
called the integrated cumulative hazard. From equation [3.5], the cumulative hazard can 
be obtained from the survivor function, since 
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   tStH log .                                                                                                            [3.7] 
3.2.3. Non-Parametric Procedures 
An initial step in the analysis of a set of survival data is to present numerical or graphical 
summaries of the survival times for individuals in a particular group. Such summaries 
may be of interest in their own right, or as a precursor to a more detailed analysis of data. 
Survival data are conveniently summarized through estimates of the survivor function 
and hazard function. Methods for estimating these functions from a single sample of 
survival data are said to be non-parametric or distribution free, since they do not require 
specific assumptions to be made about the underlying distribution of the survival times 
[10]. 
3.2.3.1.Estimation of Survivor and Hazard Functions  
In practice, when using actual data, we usually obtain estimated survivor function and 
curves that are step functions, rather than smooth curves. Among  the  other  estimators  
of  the  survivor  function  the  Kaplan-Meier  estimator  is  the  most common  one.  The 
Kaplan-Meier estimator of the survivorship function [Kaplan and Meier (1958)] also 
called product limit estimator, is the estimator used by most software packages. This 
estimator incorporates information from all of the observations available, both 
uncensored and censored, by considering survival to any point in time as a series of steps 
defined by the observed survival and censored times [30]. 
Assume  we  have  a  sample  of  n independent  observations,  their  survival times  
denoted  by ntttt ,....,, 321 and indicator of censoring by n ,....,, 321 where 1i , if an 
event/death occurs and 0i  otherwise.  Thus, the survival data are denoted by  iit ,
ni ,....3,2,1 . The first step to obtain the Kaplan-Meier estimator of the survival function 
is to order the survival times as ntttt  ........321 . Assume that among the n 
observations nm  failures occurred at distinct m times. Then the rank- ordered failure 
times are mtttt  ........321 . 
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Let in  the number at risk of dying or failure at it ; id the number of failures (deaths) at
it . Then the Kaplan-Meier estimator of the survival function at time t is obtained from 
the equation, 
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With the convention that   1ˆ tSKM  if  1tt   Thus, 
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The  variance  of  the  Kaplan-Meier  estimators  which  is  referred  to  as  Greenwood‘s  
formula  is given as: 
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Similarly, [1], [48], [49], and [3] have proposed an alternative estimator of  tH that 
refers to as the Nelson-Aalen estimator. It is formulated as: 
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It is merely in the case of small samples that the Nelson-Aalen estimate of the survivor 
function prevails over the KM estimate [30]. 
3.2.3.2.Estimating Median and Percentiles of Survival Times 
Since the distribution of survival time tends to be positively skewed, the median is 
preferred for a summary measure of the location of the distribution. The median survival 
time is the time, beyond which 50% of the individuals in the population under study are 
expected to survive, and is given by the value  50t  at which is such that    5.050 tS
[10]. 
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The estimated median survival time is given by     5.0ˆ|min50ˆ  ii tStt . Where it is 
the observed survival time for the thi  individual, ni ,.....,3,2,1 . In general, the estimate 
of the 
thp percentile is    







100
1ˆ|minˆ
p
tStpt ii . 
Approximate confidence intervals for the median and other percentiles of a distribution 
of survival times can be found once the variance of the estimated percentile has been 
obtained. An expression for the approximate variance of a percentile can be derived 
from a direct application of the general result for the approximate variance of function of 
random variable in the following equation. The variance of a function  xg of the 
random variable X is given by   
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Where,  pt is the thp percentile of the distribution and   ptSˆ  is the Kaplan-Meier 
estimate of the survivor function. 
The standard error of  ptˆ is therefore given by   
  
   ptSSE
ptf
ptSE ˆˆ
ˆ
1ˆ   
The standard error of   ptSˆ can be obtained using Greenwood‘s formula, given in 
equation [3.10], while an estimate of the probability density function at  ptˆ is 
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for ,,...,3,2,1 rj  and small value of  
In many cases, taking 05.0 will be satisfactory, but a larger value of   will be 
needed if  puˆ and  plˆ turn out to be equal. Therefore, for median survival time,  50uˆ is 
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the largest observed survival time from the K-M curve for which   55.0ˆ tS  and  50lˆ
is the smallest observed survival time from the K-M curve for which   45.0ˆ tS . The 
95% confidence interval for the 
thp  percentile  ptˆ  has limits of     ptSEpt ˆ96.1ˆ  . 
3.2.3.3.Non-Parametric Comparison of Survivorship Functions  
In  clinical  research  one  is  concerned  not only  with  estimating  the  survival  
function  but,  more often, with the comparison of the life experience of two or more 
groups of subjects differing for a given characteristic or randomly allocated to different 
treatments. After providing a description of the overall survival experience in the study, 
we usually turn our attention to a comparison of the survivorship experience in key 
subjects in the data. The simplest way of comparing the survival times obtained from 
two or more groups is to plot the Kaplan-Meier curves for these groups on the same 
graph [56]. However, this graph does not allow us to say, with any confidence, whether 
or not there is a real difference between the groups. The observed difference may be a 
true difference, but equally, it could also be due to chance. Assessing whether or not 
there is a real  difference  between  groups  can  only  be  done,  with  any  degree  of  
confidence,  by  utilizing statistical tests. Since survival data are typically right skewed, 
we would likely use rank-based non-parametric  tests  followed  by  estimates  and  
confidence  intervals  of  the  medians  or  other quantiles  within  groups.  Modifications 
of these procedures are required when censored observations are present in the data. 
When we compare groups of subjects, it is always good to begin with a graphical display 
of the data in each group. Among the various non-parametric tests one can find in the 
statistical literature, the Mantel-Haenzel (1959) test, currently called the ―logrank‖ test 
will be used. Nowadays,  the Kaplan-Meier method for estimating survival curves and 
the  log-rank  test  for  comparing  two  estimated  survival  curves  are  the  most  
frequently  used statistical tools in medical reports on survival data [30]. 
Log-rank test 
The log rank test, developed by Mantel and Haenszel, is a non-parametric test for 
comparing two or more independent survival curves. Since it is a non-parametric test, no 
assumption about the distributional form of the data is required.  This test is however 
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most powerful when used for non-overlapping survival curves. This test can be 
generalized to accommodate other tests that are equally  used  sometime  in  practice  
such  as  Generalized  Wilcoxon  test,  Tarone-Ware  test,  and Peto-Peto-Prentice test. 
Each of these tests uses different weights to adjust for censoring that is often 
encountered in survival data. For instance, the Wilcoxon test weights the
thj  failure time 
by jn (the number still at risk), the Tarone–Ware test weights the
thj  failure time by
jn  
and the PetoPeto-Prentice test weights the
thj  failure time by the survival estimate   jtS
~
 
calculated over all groups combined [40] and [30]. The log rank test statistic for 
comparing two groups is given by: 
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Where:-   
 m is the number of rank ordered events (death) times 
 id1 is the ordered number of events(death group 1 at event time it ). 
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 11ˆ is the expected number of evets (death) corresponding to id1 . 
 in1 is the number of individuals at risk in group1 just prior to event (death) time it . 
 in2  is the number of indiviuals at risk in group 2 just prior to event (deth) time it . 
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nn
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v Is the variance of the nfumber of events d1 at time it . 
 in  and id  are the number of individuals at risk and number of deah in both  groups      
(i.e., group1 and group 2) just prior to time it  respectively. 
Under the null hypothesis that two survival functions are equal, the log rank test statistic 
Q has an approximation of chi-square distribution with one degree of freedom (  
2
1 ) for 
large samples. The null hypothesis of equality of survival functions will be rejected for 
large values of Q. The most frequently used test is based on weights equal to one 1iw
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. Note  that  the  log-rank  test  can  be  extended  for  comparing  three  or  more  groups  
of  survival experience. 
3.2.4. Modeling Survival Data 
The non-parametric methods can be useful in the analysis of a single sample of survival 
data, or in the comparison of two or more groups of survival times. However, in most 
medical studies that gives rise to survival data, supplementary information will also be 
recorded on each individual [10]. In this particular study, some socio-economic, 
demographic, and health factors may all have an impact on the time that the patients 
survives. Accordingly, the values of these factors(variables), which are reffered to as 
explanatory variables, have been recorded at the onset of the study. In order to explore 
the relationship between the survival experience of a patient and explanatory variables, 
an approach based on statistical modelling have been used. 
Through a modellng approach to the analysis of survival data, we  can explore how the 
survival experience of agroup of patients depends on the values of one or more 
explanatory variables, whose values have been recorded for each patient  at the origin 
[10]. In this study, one of the objectives is to determine which of the given explanatory 
variables have an impact on the survival time of the patients. 
3.2.4.1.Modelling the Hazard Function 
In the analysis of survival data, interest centres on the risk or hazard of death at any time 
after the time origion of the study. As a consequence, the hazard function is modelled 
directly in survival analysis. The resulting models are somewhat different in form from 
liear models encountered in regression analysis and in the analysis of  data from designed 
experiment, where the dependence of the mean response, or some function of it, on 
certain explanatory variables is modelled. However, many of the principles and 
procedures used in linear modelling cary over to the modelling of survival data [10]. 
Objectives of modelling survival data 
 To determine which combiation of potential explanatory variables affect the form 
of the hazard function. 
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 To obtain an estimate of the hazard function itself for an individual so that the 
survivor function can be found. 
This will in turn lead to an estimate of the quantities such as the median survival time, 
which will be a function of the explanatory variables  in the model. The median survival 
survival time could then be estimated for the current or future patients with particular 
values of the explanatory variables. The resulting estimate could be particularly useful in 
counselling the patient about their prognosis [10]. 
The Cox Proportional Hazards Model 
The Cox Proportional Hazard (PH) Model is a multiple regression method and is used to 
evaluate the effect of multiple covariates on the survival [13]. Cox (1972) proposed a 
semiparametric  model  for  the  hazard  function  that  allows  the  addition  of  
covariates,  while keeping  the  baseline  hazards  unspecified  and  can  take  only  
positive  values  and  it  is defined as 
    XethXth '0,,
  ,                                                                                                 [3.13] 
where  ,, Xth  is the hazard function at time t with covariates  PXXXX ,....., 21
|  . 
 th0  is the arbitrary baseline hazard function that characterizes how the hazard function 
changes as a function of survival time. 
 p ,.....,, 21|   is a vector of p regression parameters associated with explanatory 
variables. 
Xe ' characterizes how the hazard function changes as a function of subject covariates.  
   T is the failure time.  
Each  individual  has  its  own  hazard  function  of  survival  time.  Then,  the  above  
model becomes 
      nixxxthXth ippii ,...,2,1,...exp,, 22110                                         [3.14] 
where:  n is total number of observations in the study.  
 ipiii xxxx ,...,, 21|   is a vector of measured covariates for the thi individual (patient) 
which are assumed to affect the survival probability. 
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The  Cox  proportional  hazard  model  is  popular  because  it  allows  a  flexible  choice  
of covariates:  time  varying,  time-independent,  continuous  and  discrete.  Two  other  
issues that  makes  it  popular  are  that  it  does  not  make  any assumption  about  the  
underlying survival  distribution  and  also  does  not  require  estimation  of  the  
baseline  hazard  rate,  th0   to estimate the regression parameters. 
Assumptions of Cox Proportional Hazards Model 
 The baseline hazard function  th0  depends on t , but not on covariates Pxxx ,...,, 21  
 The hazard ratio,  e , depends on the covariates   PXXXX ,...,, 21
|  not on time. 
 The covariates iX  are time-independent. 
Because of the 2
nd
  assumption it is called a proportional hazards model. To show this 
issue mathematically, consider two distinct values of a continuous covariate X, say, 
i1x
and 2ix  
, Then the hazard ratio becomes  
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                                                                         [3.15] 
which is clearly independent of time.  
This reveals that the ratio of the hazard functions for two individuals with different 
covariate values does not vary with time. 
Fitting the Cox Proportional Hazards Model 
The  data  in  survival  analysis  based  on  the  sample  size  n  are  denoted  by  the  
triplet  iii xt ,,  , ni ,...,2,1   where it is the time at which the
thi  individual dies from 
the disease of interest, i  is the event indicator i =1 if the event has occurred and i =0 
if it is censored (the lifetime may be right, left or interval censored), and ix    is the vector 
of covariates or the risk factors for the thi individual. 
The  Cox  model   will  be  fitted  by  estimating  the  unknown  regression  coefficients  
through  the maximum likelihood method. The actual likelihood function is constructed 
by considering the contribution  of  the  probability  that  a  subject  with  covariate  value  
    XethXth '0,,
 
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x  dies  from  the  disease of interest at time t (i.e.,  Xtf ,,  ), and the probability that a 
subject with covariate value  x survives at least  t  time units (i .e.,  XtS ,,  ). That is, 
under the assumption of independent observations, the  full  likelihood  function  is  
obtained  by  multiplying  the  respective contributions  of  the observed triplets, a value 
of   Xtf ,,  for a noncensored observation and a value of  XtS ,,  for censored 
observations. 
Thus, the contribution of each triplet to the likelihood is the expression 
                                                     [3.16] 
Since the observations are assumed to be independent, the likelihood function is the 
product of the expression in [3.16] over the entire sample and is formulated as: 
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Thus the full likelihood function after some computations over equation [3.18] (See [10]) 
is then given by the expression: 
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Cox (1972) proposed using an expression he called a partial likelihood function due to 
the fact that  the likelihood formula considers probabilities only for those subjects who 
fail, and does not explicitly  consider  probabilities  for  those  subjects  who  are  
censored.  In  other  words,  the likelihood for the Cox model does not consider 
probabilities for all subjects.  Let us consider a sample of  n  subjects and suppose a total 
of  m  failures occur, with  m  smaller than  n, due to the presence of censoring. Let 
mttt  ...21 be the m distinct ordered failure times observed and let  itR be the 
set of  individuals  at thi failure time, which consists of all subjects with survival or 
censored times greater than or equal to the specified time [30]. 
      ii XtSXtf    1,,,,
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The expression in equation [3.19] assumes that there are no tied times, and it is often 
modified to exclude terms when i =0, yielding the partial likelihood function given as 
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To obtain the maximized partial likelihood function with respect to the parameters of 
interest, β, we maximize the log partial likelihood function in equation [3.21]. 
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We obtain the maximum partial likelihood estimator by differentiating the right hand side 
of [3.21] with respect to β, setting the derivatives equal to zero and solving for the 
unknown parameters. This is known as the Newton-Raphson iterative method.  
That is, for each derivative 
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U (β) is called the score or gradient vector. The solution to the equation [3.22] is denoted 
by ˆ . The estimator of the variance of the estimator of the coefficient is obtained in the 
same manner as  variance  estimators  are  obtained  in  most  maximum  likelihood  
estimation  applications.  The estimator is the inverse of the negative of the second 
derivative of the log partial likelihood at  the value of the estimator. Derivation of the 
expression in [3.22], will result in 
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The expression in [3.23] shall be simplified using  ijw  in equation [3.22] above. That 
is, 
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The negative of the 2
nd
 derivative of the log partial likelihood in either [3.23] or [3.24] is 
known as the observed information and denoted by 
 
 
2
2






pl
I                                                                                                        [3.25] 
If we consider models that contain more than one covariate, the result in [3.25] becomes
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I which is known as the observed information matrix (Hessian matrix). 
According to the Newton-Raphson procedure an estimate of β at the  thj 1 of the 
iterative procedure, 1
ˆ
j , is     ,...2,1,0,ˆˆˆˆ 11   jUI jjjj  . As a result, the 
estimator of the variance of the estimated coefficient is the inverse of [3.25] evaluated at 
ˆ and is  
    1ˆˆˆ   IarV                                                                                                            [3.26] 
Model Diagnostics for Cox PH Model 
Model-based  inferences  depend  completely  on  the  fitted  statistical  model.  For  these 
inferences to be valid in any sense of the word, the fitted model must provide an adequate 
summary  of  the  data  upon  which  it  is  based.  The  methods  for  assessment  of  a  
fitted proportional  hazards  model  are  essentially  the  same as  for  other  regression  
models [30]. 
Residuals  are  used  to  investigate  the  lack  of  fit  of  a  model  and  useful  for  
examining different  aspects  of  the  model.  The  following  residuals  have  been  
proposed  for  use  by different authors in connection with the Cox regression model. 
Cox-Snell, Martingale, and Deviance Residuals  
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The Cox-Snell residual for the thi individual is given as    tStHr iici
ˆlnˆ  , where 
 tH iˆ and  tSiˆ are the estimated values of the cumulative hazard and survivor functions 
of the thi  individual at time t respectively. The Cox-Snell residuals will not be 
symmetrically distributed about zero and cannot be negative. Hence, the plot of the 
cummulative hazard of Cox-Snell residuals,  
ic
rH versus Cox-Snell residuals,
ic
r  gives a 
straight line with unit slope and zero intercept if the fitted model is correct [12].  
The martingale residual is a slight modification of the Cox-Snell residuals and is defined 
as 
ii cim
rr    where, i  is  the  censoring  indicator  and icr  is  Cox-Snell  residual 
[5]. The martingale residuals take values between negative infinity and unity. They are 
uncorrelated and also have a skewed distribution with mean zero in large samples. In this 
respect they have properties similar to those possessed by residuals encountered in linear 
regression analysis [4], [10]. 
The deviance residuals are a normalized transformation of the martingale residuals. The 
deviance residual for the thi  individual is defined by:- 
      21log2
iiii miimmD
rrrsignr   , 
Where, the function  sign  is the sign function which takes the value 1 if the martingale 
residual, 
im
r is positive and -1 if 
im
r is negative; and 1i for uncensored observation, 
0i for censored observation. The deviance residuals also have a mean of zero but are 
approximately symmetrically distributed about zero when the fitted model is appropriate. 
Deviance residual can also be used like residuals from linear regression. The plot of the 
deviance residuals against the covariates can be obtained. Any unusual patterns may 
suggest features of the data that have not been adequately fitted for the model. Very large 
or very small values suggest that the observation may be an outlier in need of special 
attention. In a fitted Cox PH model, the hazard of death for the thi  individual at any time 
depends on the value of  ix exp  which is called the risk score. A plot of the deviance 
residuals versus the risk score is a helpful diagnostic to assess a given individual on the 
model. Potential outliers will have deviance residuals whose absolute values are very 
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large. This plot will give the information about the characteristic of observations that are 
not well fitted by the model [70]. 
 
Schoenfeld Residuals  
This overcomes the problem that the above three residuals depend heavily  on observed 
survival time  and cumulative hazard  function. They  are computed for  each  individual  
and  covariate.  It  follows  that, the  Schoenfeld  residual  for  the thi individual and thk  
covariate is defined as: 
 
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                                                                          [3.27] 
where, jX  is a vector of p fixed covariates for the 
thj individual, jkx  is the value of 
thk
covariate on the 
thj  individual.  
Because of that, Schoenfeld residuals are defined only for the uncensored observations in 
which case 
 
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 and  for  each  covariate  it  must  sum  to  zero.  In 
addition, they are uncorrelated and with expected value zero [58].  
Most of the model diagnostics in survival data are based on the residuals stated above. 
The following are  model diagnostics that are required to assess the model adequacy in 
this particular study. 
Testing for the Nonlinearity of Covariates 
After identifying a particular set of explanatory variables on which the hazard function 
depends, it is desirable to check whether the correct functional form has been adopted for 
the continuous  covariates.  The  Martingale  residuals  can be  plotted  against  covariates  
to detect  nonlinearity.   Nonlinearity  is  not  an  issue  for  categorical  variables,  so  we  
only examine  plots  of  martingale  residuals  against  continuous  covariate.  LOESS  
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smoothed curve  can  be  superimposed  on  the  scatter  plots  to  give  interpretation.  If  
the  functional form observed in using the plots has some pattern,  which is non linear, 
the covariate can be  so  transformed  and  the  martingale  residuals  again  should  be  
plotted  against  the transformed covariate. A horizontal straight line which is drawn as a 
reference through zero  would  then  confirm  that  the  appropriate  transformation  has  
been  used  to  the covariate.  In  addition,  if  the  resulting  smooth  plot  is  a  straight  
line  compared  to  the reference line, then it shows linearity [10]. 
Examining Influential Observations 
Another important aspect of model evaluation is through diagnostic statistics in order to 
identify which subjects have an unusual configuration of covariates or observations that 
have  influence on  the  estimates  of  the  parameters  or  on  the  fit  of  the  model.  In  
other words a fitted model is particularly sensitive to one or more observations in the data 
set. Such observations can be termed as influential observations. Conclusions from 
survival analyses are often framed in terms of estimates of  the relative hazard, which 
depends on the estimated values of the coefficients in the Coxregression model. Thus, it 
is desirable to  examine  the  influence  of  each  observation  on  these  estimates.  The  
interest  is  about observations that influence estimate of hazard functions and the 
complete estimate of the model and identifications of these observations. This could be 
done by fitting the model to all  n observations in the data set, and then fitting the same 
model to the sets of  n-1observations obtained by omitting each of the  n observations in 
turn. The interest is to determine if the result would change when a particular observation 
is removed from the analysis [10]. 
Suppose  that   pl  in equation [3.21] is  log  partial  likelihood  and jˆ is  the  
corresponding 
thj parameter estimate  of  the  model  containing  all  the  n  observations  
and   ipl   be  the  log  partial likelihood and  ij ˆ is the 
thj  parameter estimate of the 
model containing only the 1n observations  after  deleting  the thi observation,  
respectively.  Then,  the  statistic  ijjji  
ˆˆˆ , which is known as DFBETA, can 
be used as a measure of how the 
thj parameter estimate would change if the thi
observation was deleted from the data set. On the  other  hand,  the  statistic,
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   ippi llLD   22 ,  which  is  called  the  likelihood displacement  statistic,  can  
be  used  as  a  measure  of how  the  maximized  partial  log likelihood changes if the thi
observation was deleted from the data set. Observations that influence a particular 
parameter estimate have a  large absolute value of  DFBETA than other  observations  in  
the  data  set.  Observations  that  do  influence  the  overall  fit  of  the model  are  those  
which  have  large  values  of  likelihood  displacement  statistics  than  the other 
observations in the data set [10]. 
Checking Cox Proportional Hazard Assumption 
In order to use the Cox model, it has to be checked that the assumption of whether the 
effects of covariates on hazard ratio remain constant over time. This is a vital assumption 
of  proportional  hazards  model  and  must  be  assessed  for  each  covariate.  Several 
procedures  of  graphical  techniques  and  tests  are  proposed  to  investigate  the 
proportionality  assumptions  in  fitting  the  Cox  model  [13].  The  Schoenfeld residuals 
are employed to assess this assumption. 
The  Schoenfeld  residuals  graphical  technique  can  be used  to  assess  Cox  model 
proportionality assumption. The technique is based on individual contributions to the 
logpartial likelihood and measures the difference between the covariate for the thi
individual and  a  weighted  average  of  the  covariate  over  the  risk  set  at  each  event.  
To  check  the proportionality  assumption  for  each  covariate,  we  plot  the  scaled  
Schoenfeld  residuals against  log  of  survival  time.  If  the  proportional  hazards  
assumption  is  satisfied,  the distribution of residuals over time is random, i.e., it does not 
show a particular trend, and the  smoothed  plot  called  Locally  Weighted  scatterplot 
smoothing  (LOWESS)  line summarizing the residuals should be a straight line and close 
to the horizontal reference line. Otherwise, a plot of scaled Schoenfeld residuals for a 
given covariate may reveal a violation of the proportional hazards assumption [58]. 
Formal tests need to detect any time dependency in  particular covariates, after allowing 
for  the  effects  of  explanatory  variables  that  are  known.  Testing  the  dependency  of 
covariates  on  time  is  equivalent  to  testing  for  a  non-zero  slope  in  a  generalized  
linear regression of the scaled Schoenfeld residuals on functions of time. A non-zero 
slope is an indication of a violation of the proportional hazard assumption. The 
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Grambsch-Therneau test  of  non-proportionality  uses  partial  residuals  for  the  test  of  
proportional  hazards assumption. In order to use this test for the thi covariate, Grambsch 
and Therneau (1994) propose a time-varying coefficient as    tgt iiii   . Where  
 ti is  time  varying  coefficient, i  is  constant,  and   tgi  is  some  specified function 
of time, usually    ttg i ln ;  Then, the Cox proportional hazard model for time 
varying coefficient with    ttg i ln is defined as 
       xtthtxth iii  exp,, 0 , by substituting for  ti and  tg i becomes 
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ii
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                                                               [3.28] 
Equation [3.28] is the proportional hazards model with the interaction term,  tx ln  and 
main effect ix . To test the significance of the interaction term  tx ln , we perform the test: 
0:,,0: 10   HversusH  and we use likelihood-based tests like Wald test.  If  
γ= 0 is not rejected, si '  are not time varying coefficients and hence the proportional 
hazards assumption is satisfied. If γ= 0 is rejected then the proportional hazards 
assumption is not satisfied,  that  leads  to  the  need  of  other  methods  that  cope  with  
time-dependency [58]. 
Strategies for Analyzing of Non-Proportional Data 
Suppose those statistical tests or other diagnostic techniques give strong evidence of non- 
proportionality for one or more covariates. To deal with this there are two popular 
methods: stratified Cox model and Cox regression model with time-dependent covariate 
which are particularly simple and can be done using available statistical software. 
Another alternative to consider is to use a different model. A parametric model such as an 
AFT model, which we will describe in next section, is more appropriate. And hence, this 
alternative will be considerd in such cases in this particular thesis. 
3.2.4.2.Parametric Regression Models for Survival Data 
The rationale for using either nonparametric or semiparametric models, in particular the 
semiparametric proportional hazards regression model, is to avoid having to specify the 
hazard function completely. The utility of the proportional hazards model stems from the 
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fact that a reduced set of assumptions is needed to provide the hazard ratios formed from 
the coefficients that are easily interpreted and clinically meaningful. However, there may 
be settings in which the distribution of survival time, through previous research, has a 
known parametric form that justi fies use of a fully parametric model to better address the 
goals of the analysis. These models have some advantages. In particular,  
 full maximum likelihood may be used to estimate the parameters. 
  the coefficients can be clinically meaningful and, for some models, are re lated to 
those from a proportional hazards model. 
 fitted values from the model can provide estimates of survival time. 
  residuals can be computed that are differences between observed and predicted 
values of time.  
The result is that an analysis using a fully parametric model can have the look and feel of 
a normal errors linear regression analysis [30]. 
Survival time models that can be linearized by taking logs are called accelerated failure 
time models. The reason for this terminology is that the effect of the covariate is 
multiplicative on the time scale. That is, the effect of the covariate is associated with 
either "accelerated" or ―decelerated‖ failure time. Where as, in the proportional hazards 
model, the effect of the covariates is multiplicative on the hazard scale [30]. 
The Gompertz PH Model 
The survival and hazard function of the Gompertz distribution are given by:- 
        lyrespective  exp  and 1exp  tthtS e t 
 






  
0 and 0For  t . The parameter determines the shape of the hazard function. 
When 0 , the survival time then has an exponential distribution, i.e., the exponential 
distribution is also a special case of the Gompertz distribution. Like the Weibull hazard 
function, the Gompertz hazard increases or decreases monotonically. For the Gompertz 
distribution   thlog  is linear with t . 
Under the Gompertz PH model, the hazard function of a particular patient is given by 
         tXxxxtXth pp  expexp...exp exp 2211   . 
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It is straightforward to see that the Gompertz distribution has the PH property. But the 
Gompertz PH model is rarely used in practice. 
Most computer software for fitting the exponential and Weibull models uses a different 
form of the model, AFT model, which we will describe it in the next section. 
The Accelerated Failure Time Models 
Although the PH model finds widespread applicability in the analysis of survival data, 
there are relatively few probability distributions for the survival times that can be used 
with this model. A model that encompasses a wide range of survival time distributions is 
the AFT model. In circumstances where the PH assumption is not tenable, models based 
on this general family may prove to be fruitful. Again, The Weibull distribution which 
includes exponential distribution as a special case may be adopted for distribution of 
survival times in AFT models, but some other probability distributions are also available 
[10]. 
Parametric AFT models are unified by the adoption of a log-linear representation of the 
model. This representation shows that the AFT model for survival data is closely related 
to the general linear model used in regression analysis. Moreover, this form of the model 
is adopted by most computer software packages for AFT modeling [10]. 
The AFT model for survival time assumes that the relationship of logarithm of survival 
time iT , associated with the life time of the 
thi individual in a study and the corresponding 
covariates is linear and can be written as 
ipipiii xxxT   .  .  . log 2211                                                     [3.30] 
In this model, are .,  .  . ,, 21 p  the unknown coefficients of the values of p 
explanatory variables, pXXX .,  .  . ,, 21 , and are   ,  two further parameters, known as 
the intercept and scale parameter, respectively. The quantity is i a random variable used 
to model the deviation of the values of iTlog from the linear part of the model, and is i
assumed to have a particular probability distribution. In this formulation of the model, the 
α-parameters reflect the effect that each explanatory variable has on the survival times; 
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positive values suggest that the survival time increases with the values of the explanatory 
variable, and vice versa. 
The general form of  the survivor and the corresponding hazard function for the thi
individual in an AFT model to situations where the values of p explanatory variables 
have been recorded for each individual in the study can be derived from the log-linear 
formulation in equation [3.30]. And it is given by 
      
 
      
 
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     [3.31]                                                   ,                                                            
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Equation [3.31] is the general form of the survivor function for the thi individual in an 
AFT model; the acceleration factor is  ix'exp   for the 
thi  individual. The 
corresponding relationship between the hazard functions is obtained by taking natural 
logarithms of sides of equation [3.31], multiplying by -1, and differentiating with respect 
to t, leads to 
      ixtii hxth 'exp0'exp  ,                                                                                 [3.32] 
A general expression for the 
thp percentile of the distribution of survival times in AFT 
models follows from the result that an AFT model can be derived from many probability 
distributions for i , although some are more tractable than others. 
This can be shown as follows 
 45 
 
     
   
[3.33]                                       
.  .  . log
         
,log.  .  . 
 [3.30],equation  From
.loglog
2211
2211







 







pipii
i
ipipiii
iii
xxxt
P
txxxPtS
tTPtTPtS
If we now write   iS for the survivor function of the random variable i
 in the log-
linear model of equation [3.30], the survivor function of the thi individual can, form 
equation [3.33], be expressed as  
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Equation [3.34] shows how the survivor function for iT  can be found from the survivor 
function of the distribution of i . Then the 
thp  percentile for the thi individual,  pti , is 
given by 
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    pipiiii xxxppt   .  .  . exp 2211                                         [3.35] 
equation [3.35] is the general expression for the 
thp  percentile for the thi individual, 
 pti  in AFT model. It can be written in the form  
     ptxxxpt pipiii 02211 .  .  . exp   ,                                                        [3.36] 
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Where  pt0 is 
thp percentile for a baseline individual for whom all explanatory variables 
take the value zero. This confirms that the α-coefficients can be interpreted in terms of 
the effect of the explanatory variables on a particular percentile of survival times [10]. 
Particular choices for the distribution of i in the log-linear formulation of the AFT model 
equation [3.30], leads to distributions for the random variable associated with the survival 
time of the thi  individual. Parametric AFT models based on the Weibull, log-logistic and 
log-normal distributions for the survival times are most commonly used in practice. 
The Weibull AFT Model 
The Weibull distribution which includes the exponential distribution as a special case can 
also be parameterized as an AFT model, and they are the only family of distributions to 
have both PH and AFT property. The results of fitting a Weibull model can therefore be 
interpreted in either framework. Then the Weibull distribution is very flexible model for 
time-to-event data. It has a hazard rate which is monotonically increasing or decreasing 
and constant when the shape parameter 1 . If  iii xT   'exp has a 
Weibull distribution In terms of the log-linear representation of the model in equation 
[3.30], then i does in fact have a type of extreme value distribution known as Gumbel 
distribution. This is an asymmetric distribution with survivor function given by: 
       -for  , exp eS i                                                                        [3.37] 
Then form equation [3.34], the survivor function of iT is given by: 
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This can be expressed in the form 
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is the scale parameter and 1 is 
shape parameter. 
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The cummulative hazard can be obtained as follows: 
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Which can also be expressed as 
1
ti and the hazard function is obtained by 
defferentiating the cummulative hazard with respect to t and hence it is given as follows: 
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Or   11
1    tth ii .  
We now reconcile this form of the model with that for the Weibull PH model. From 
equation [3.29], above the survivor function for the thi individual is 
     txxxtS pipiii  .  .  . expexp 2211 ,                                              [3.40] 
In which  and are parameters of the Weibull baseline hazard function. There is a direct 
correspondence between equation [3.38] and [3.40] in the sense that 
,        ,      , exp j
1-




 j





 for p , .  .   . ,2 ,1j  
We therefore deduce that the log-linear model in which i has Gumbel distribution, 
provides an alternative representation of the Weibull PH model. 
In this form of the model, the 
thp percentile of the survival time distribution for the thi
individual is the value  pti  , which is such that    





100
1
p
ptS ii , where  tS i is 
as given in equation [3.38] straightforward algebra leads to the result that 
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The Log-Logistic AFT Model 
The log-logistic distribution provides the most commonly used AFT model. Unlike the 
Weibull distribution, it can exhibit a non-monotonic hazard function which increases at 
early times and decreases at later times. It is similar in shape to the log-normal 
distribution but its cumulative distribution function has a simple closed form, which 
becomes important computationally when fitting data with censoring [36]. 
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When the survival times have log-logistic distribution with parameters k  ,  , then the 
baseline hazard function is given by: 
 
k
k
te
kte
th





1
1
0                                                                                                          [3.42] 
And the corresponding survivor function is 
 
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tS
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
1
1
0
                                                                                                         [3.43] 
The log-linear form of the accelerated time model in equation [3.30] also provides a 
representation of the log-logistic distribution. Suppose that in this formulation, i now 
has a logistic distribution with zero mean and variance
3
2 , so that the survivor function 
of i is     e
S
i 

1
1
. 
Using equation [3.34], the survivor function of iT is then 
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From equation [3.31] and [3.43], the survivor function of iT , is derived as follows:  
 
kki te
tS
i 

1
1
.                                                                        [3.45] 
It then follows that iT has a log-logistic distribution with parameters ik  , k .where
pipiii xxx   ...2211 . The log-logistic distribution therefore has the AFT 
property. However, this distribution doesn‘t have the PH property [10].  
On comparing expression [3.45] with that for the survivor function in equation [3.44], we 
see that the parameters k and  can be expressed in terms of   and . Specifically,  

   , 

1k                                                                                                  [3.46] 
Where with k>0; When 1k , the hazard rate decreases monotonically and when k>1, it 
increases from zero to a maximum and then decreases to zero. 
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The hazard function for the thi individual is obtained by applying log to the survivor 
function in equation [3.44] and multiplying by -1 then differentiating the result with 
respect to t gives 
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And the 
thp percentile of the survival time distribution is from equation [3.44], or the 
general result in equation [3.35], is 
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The median survival time can be obtained by substituting 50p in equation [3.48]. 
Note that, the natural logarithm of odds ratio in log-logistic AFT model is independent of 
time. Therefore, the log-logistic regression model is a proportional odds model, not a 
proportional hazards model. i.e., the log-logistic model is the only parametric model with 
both a proportional odds and an accelerated failure-time representation [35]. And hence 
using equation [3.43], the baseline odds of survival beyond t is given by
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1 0
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Similarly, using equation [3.44], the odds of survival beyond t for the thi individual is  
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Therefore, from equation [3.49], we can see that the factor  ix'exp   is an estimate of 
how much the baseline odds of survival at any time changes when an individual has 
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covariate ix . Moreover, to check whether the log-logistic distribution is tenable to fit a 
particular survival data set, a plot of 
 
 




 tS
tS
i
i
1
log versus tlog is used and it should be 
linear if the log-logistic distribution is appropriate. 
The Log-Normal AFT Model 
If the survival times are assumed to have a log-normal distribution, the baseline survival 
function is given by   




 


t
tS
log
10 , 
are  and  Where  unknown parameters. Under AFT model, the survivor function for the
thi individual, is then    teStS ii  0 , 
Where pipiii xxx   ...2211 is a linear combination of the values of p 
explanatory variables for the thi individual. Therefore,  
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tS
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1 ,                                                                                [3.50] 
which is the survivor function of an individual whose survival times have a lognormal 
distribution with parameters   and i . The lognormal distribution therefore has the 
AFT property. 
In the log-linear formulation of the model, the random variable associated with the 
survival time of the thi individual has a lognormal distribution if iTlog is normally 
distributed. We therefore take i  in equation [3.30] to have a standard normal 
distribution, so that the survivor function of i is      1iS . 
The cumulative hazard, and hazard function, of i are 
      
 
 
lyrespective , and , 1log
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i
i
ii S
f
hH   
Where   if is the density function of a standard normal random variable, given by 
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The random variable iT , in AFT model, then has a lognormal distribution with parameters
ix'  and . The survivor function of iT  is as given in equation [3.50] and the hazard 
function can be obtained from the general form in equation [3.32]. 
The 
thp percentile of the distribution of iT  , from equation [3.35], is  
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And in particular,    ixt 'exp50   is the median survival time for the 
thi
individual. 
The Generalized Gamma AFT Model 
In this section we introduce a regression model that is based on the general form of the 
gamma distribution. Therefore, in this study whenever we speak off gamma AFT model, 
we mean that the generalized gamma AFT model since it includes relatively a wide range 
of family distribution as its special case [35].   Let‘s first define some functions which 
may be used in the rest of this section. 
The gamma function is a well-known function which is defined as follows: 
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                                                          [3.51] 
Another useful function to know in this section is known as the incomplete gamma 
function and it is mathematically defined as: 
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Then, the three-parameter Generalized Gamma survivor and density functions 
respectively are 
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                                                           [3.54] 
 
 
Where     ,exp,/log)(,2 zkutksignzk     z is the standard 
normal cumulative distribution function,  xaI , is incomplete gamma function, and 
)(ksign is a mathematical function which returns the sign of k: -1 if k < 0, 0 if k= 0, 1 if k 
> 0, and missing if k is missing. In STATA, this model is implemented by parameterizing
 jj X and treating the parameters k and  as ancillary parameters to be estimated 
from the data. 
The hazard function of the generalized gamma distribution is extremely flexible, allowing 
for many possible shapes, including as special cases the Weibull distribution when 1k , 
the exponential when 1k and 1 , and the lognormal distribution when 0k . The 
generalized gamma model is, therefore, commonly used for evaluating and selecting an 
appropriate parametric model for the data. The Wald or likelihood-ratio test can be used 
to test the hypotheses that 1k or that 0k . 
The hazard function can be found by applying log to the survivor function; multiplying 
by -1 then differentiating the result with respect to t. moreover, the 
thp percentile of the 
survival time distribution can be obtained by applying equation [3.36]. Furthermore, the 
median survival time ratio for the thj individual can be obtained by dividing the median 
survival time of that individual by the baseline median survival time and it is given by 
                                                         [3.55] 
Fitting Parametric Models 
AFT models are fitted using the method of maximum likelihood. The likelihood function 
is best derived from the log-linear representation of the model, after which iterative 
methods are used to obtain the estimates. The likelihood of the n  observed survival 
times, nttt ,...,, 21 , is form equation [3.17] given by  
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Where  ii tf and  ii tS are the density and survivor functions for the 
thi individual at it , 
and i is the event indicator for the 
thi observation, so that i is unity if the 
thi is an event 
and zero if it is censored. Now, from equation [3.34],    iii zStS i , 
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The likelihood function can then be expressed in terms of the survivor and density 
function of i , giving 
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The log-likelihood function is then 
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And the maximum likelihood estimates of the 2p unknown parameter, , and
p ,...,, 21 , are found by maximizing this function using the Newton-Raphson 
procedures. 
Checking the Adequacy of Parametric Models 
The graphical methods can be used to check if a parametric distribution fits the observed 
data. Specifically, if the survival time follows a Weibull distribution, a plot of
  tSloglog  versus tlog should yield a straight line with slope of 1. If the plots are 
parallel but not straight, then PH assumption holds but not the Weibull. If the lines for 
two groups are straight but not parallel, the Weibull assumption is supported but the PH 
and AFT assumptions are violated. The log-logistic assumption can be graphically 
evaluated by plotting      tStS1log versus tlog .If the distribution of survival 
function is log-logistic, then the resulting plot should be a straight line. For the log-
normal distribution, a plot of   tS 11 versus tlog should be linear.  
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Using Quantile-Quantile Plot 
An initial method for assessing the potential for an AFT model is to produce a quantile-
quantile plot. For any value of p  in the interval  100 ,0 , the thp percentile is
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
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 
100
1001 pSpt . Let  pt0  and  pt1 be the
thp percentiles estimated from the 
survival functions of the two groups of survival data. The percentiles for the two groups 
may be expressed as 
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Where  tS0 and  tS1 are the survival functions for the two groups. So we can get 
     
2
1
0011  ptSptS . 
Under the AFT model,    tStS 01  , and so      ptSptS 1011  . 
Therefore, we get    ptpt 1
1
0
  . 
The percentiles of the survival distributions for two groups can be estimated by the K-M 
estimates of the respective survival functions. A plot of percentiles of the K-M estimated 
survival function from one group against another should give an approximate straight line 
through the origin if the accelerated failure time model is appropriate. The slope of this 
line will be an estimate of the acceleration factor 1 [34]. 
Using Statistical Criteria 
We can use statistical tests or statistical criteria to compare all these AFT models. Nested 
models can be compared using the likelihood ratio test. The exponential model, the 
Weibull model and log-normal model are nested within gamma model. For comparing 
models that are not nested, the Akaike information criterion (AIC) can be used instead, 
which is defined as  cklAIC  22 , 
Where l  is the log-likelihood; k  is the number of covariates in the model and c  is the 
number of model-specific ancillary parameters. The addition of  ck 2  can be thought 
of as a penalty if non-predictive parameters are added to the model. Lower values of the 
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AIC suggest a better model. But there is a difficulty in using the AIC in that there are no 
formal statistical tests to compare different AIC values. When two models have very 
similar AIC values, the choice of model may be hard and external model checking or 
previous results may be required to judge the relative plausibility of the models rather 
than relying on AIC values alone [34]. 
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4. Results of Statistical Analysis and Discussions 
4.1. Data Set Summary and Descriptive Analysis 
The first step in analysis of statistical data is showing the nature of the entire data set 
using descriptive methods. However, meaningful conclusions could be drawn from the 
results of analysis on the basis of well managed data besides the reliability of the 
information gathered.   Hence, descriptive analysis has been made in order to get some 
information about the distribution of survival time between/among categories of factors 
summarized in Table: 4.1. Therefore, potential risk factors which are expected to have 
significant effect on survival of patients were predicted for further analysis by descriptive 
analysis. The baseline values of such factors were recorded for every individual patient 
made eligible for the study in the accrual period.    
For this particular study, there were 6200 patients under ART follow-up in the accrual 
period out of which only 3042 patients were eligible for the study. The remaining 3158 
patients were excluded from analysis because important attributes were not recorded for 
them. In other words, patients included for the analysis were those for whom complete 
information was recorded about their baseline characteristics and their survival status 
were known to be dead at a certain time t  or alive until the study time. Several variables 
were expected to affect the survival time of individual HIV/AIDS patients under ART 
follow-up. Some of the independent variables were basically numerical whereas others 
were categorical. Descriptive summary statistics associated with numerical covariates are 
shown in the Appendix, Table7. 1. 
Similarly, Table: 4.1 shows categorical covariates in which labels of each factor were 
assigned numerical values so that data entry was easier. The CD4 count (percent) is 
numerical by nature but it was categorized in to labels because the values associated with 
this variable were obtained in percentage for some individuals particularly, individuals of 
age less than 12 and as actual count for others. Therefore categorizing CD4 percent was 
believed to be better way and convenient for this particular study. In this regard, actual 
CD4 counts were allocated to corresponding CD4 percent category (label) in such a way 
that a CD4% of 12-15% is the same as a count of under 200 cells/mm
3
; a CD4% of 29% 
is the same as a count of over 500 cells/mm
3
 but there is a wide range for higher values; 
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CD4 counts between 200 cells/mm
3
and 500 cells/mm
3
 exclusive were categorized as CD4% of 
16-28% [
1
].  
As it can be seen from (Table7. 1 in the Appendix), summary statistics associated with 
continuous covariates were not expressed in terms of patients‘ survival time like 
categorical covariates in Table: 4.1. Rather they were given to describe average age, 
weight and household size of HIV/AIDS patients who were under ART follow-up and 
considered to be eligible for this particular study. Minimum, maximum and standard 
deviations given for each of these covariates could be helpful to have a general insight 
about age, weight and household size of individual patients in this particular study. The 
presence of independent effect of each of these continuous covariates on survival time 
has been assessed in section 4.3 by Cox PH Model (Table: 4.3). The effect for age and 
weight appeared to be significant independently whereas household size showed 
statistically insignificant effect.  
In the same manner, the independent effect of categorical covariates was assessed by 
Non-Parametric analysis as well as Cox PH model. 
 
 
 
 
 
 
 
 
 
 
                                                          
1
The immune system contains lots of different cells. The two main types of lymphocytes are T cells and B 
cells. CD4 cells are a type of T cells. So the CD4% looks at the CD4 count in relation to other immune 
cells. CD4 counts are not used for children under 12 years old, who are monitored by CD4 percentage. 
This is because we are born with very high CD4 levels (several thousand cells/mm
3
). 
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Table: 4.1: Description of Survival time by Categorical Covariates 
Covariates Label Value No. of  
Patients 
No. of 
Events 
Median 
Survival 
Time 
Gender Female 0 1790 271 124.7 
 Male 1 1252 245 112.53 
Functional Status Working 0 2042 234  
 Ambulatory 1 815 210 111.53 
 Bedridden 2 185 72 109.53 
WHO Clinical Stage I 0 129 2  
 II 1 433 23  
 III 2 1875 226  
 IV 3 605 265 103.53 
CD4 Percent 12-15% 1 2460 479 112.53 
 16-28% 2 549 37  
 Above28% 3 33 0  
Cotrimoxazol Yes 0 2418 427 123.7 
 No 1 624 89 124.7 
TB Status Negative  0 532 30  
 Positive  1 2510 486 123.7 
Marital Status Never Married 0 1074 151  
 Married 1 1950 365 112.53 
 Widowed or Divorced 2 18 0  
Educational Status Educated 0 1218 244 112.53 
 Not Educated 1 1824 272 124.7 
Opportunistic Infections No 0 42 4  
 Yes 1 3000 512 124.7 
Risk Behavior No 0 228 6        
 Yes 1 2814 510 123.7 
Occupational Status Employed 0 2814 509  124.7 
 Unemployed 1 228 7   
According to the results in Table: 4.1, differences in magnitudes of median survival time 
could be observed when Comparison is made between/among categories of covariates. 
However, it could be difficult to determine whether the observed difference is statistically 
significant. But it is possible to know which group of patients is likely to survive more in 
terms of time as compared to other group(s) defined by a particular covariate if the 
observed difference is assumed to be significant. Hence, Non-Parametric analysis was 
made in order to minimize such uncertainty in descriptive analysis of survival data and to 
predict possible set of covariates on which further analysis should be made.  
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4.2. Non-Parametric Analysis  
In this part of the analysis, Survival time of individual patients was estimated for each 
level of categorical covariates using the K-M method described in Section 3.2.3.2 and 
compared using log-rank test (Section 3.2.3.3). The K-M curves for each category of 
study factors (categorical covariates) provide an initial insight into the shape of the 
survival function for levels of study factors. The log-rank test is used to compare survival 
time distributions among categories. The K-M estimate of the survivor function curves 
for Gender of patients is shown in Figure: 4.1. Similarly, K-M curves based on separate 
calculation of survivor functions by groups defined by each of other categorical 
covariates are shown in (Appendix, Figure7. 1). The corresponding log-rank test result 
which has been used to compare survival distribution is given in Table: 4.2. 
 
Figure: 4.1 : K-M Estimate of the Survivor Function for Categories of Gender 
According to the result in Table: 4.2, by the log-rank test for equality of survivor function 
between Male and Female the p-value was 0.011 which is associated with high value of 
calculated chi-square. Therefore, there is statistically significant difference in the 
distribution of survival time between male and female at 5% level of significance. The 
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same way as it was described in Table: 4.1, Figure: 4.1 also showed that Female patients 
are more likely to survive longer than Male patients. However, adjusted effect of Gender 
appeared to be insignificant by Semi-Parametric and Parametric analysis in which the 
effect of a particular factor is assessed relative to all other covariates considered in the 
analysis (Section4.3). 
Furthermore, Functional Status, WHO clinical Stage, CD4 Percent, TB Status, Educational 
Status, Opportunistic Infections and Risk Behavior were identified to have statistically 
significant effect by Non-Parametric analysis. However, adjusted effect of Educational 
Status was insignificant as it could be shown in the next section. The P-Values for 
Educational Status and Risk Behavior were 0.008 and 0.007 respectively. Whereas, 
Functional Status, WHO clinical Stage, CD4 Percent, TB Status and Opportunistic 
Infections have, P-Value=0.000 (See Table: 4.2). 
Table: 4.2: Independent Log-Rank Test for equality of survival distributions for the 
different levels of Categorical Covariates 
Categorical Covariates Chi-Square df P-value 
Gender 6.548 1 .011 
Functional Status 80.363 2 .000 
WHO Clinical Stage 370.965 3 .000 
CD4 Percent 33.724 2 .000 
Cotrimoxazol 2.748 1 .097 
TB Status 22.021 1 .000 
Marital Status. 2.119 2 .347 
Educational Status 6.929 1 .008 
Occupational Status .242 1 .623 
Opportunistic Infections 13.327 1 .000 
Risk Behavior 7.337 1 .007 
In other words, the remaining categorical covariates such as Cotrimoxazol, Marital Status 
and Occupational Status which were expected to have effect on survival of individual 
HIV/AIDS patients at the beginning of the study were predicted to be insignificant at 5% 
level of significance by the Non-Parametric analysis in this particular study. The effect of 
continuous covariates Age, Weight and Household Size was of course not assessed yet by 
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the Non-Parametric analysis. However, all covariates were assessed once again by the 
Cox PH model independently as well as in a conditional (adjusted) manner in Section4.3.   
4.3. Cox PH Model 
In section 4.2, patients‘ survival time distribution has been compared between/among 
categories of each covariate independently on Non-Parametric basis. Here, the effect of 
such factors including continuous covariates was assessed by using Cox PH model 
independently as well as relatively. As predicted by the Non-Parametric Analysis, 
Gender, Functional Status, WHO clinical Stage, CD4 Percent, TB Status, Educational 
Status, Opportunistic Infections and Risk Behavior were significant in Cox PH model 
analysis independently. Age, Weight and Household size were also identified to have 
significant effect by the Cox PH model in the independent analysis (See Table: 4.3). 
Cotrimoxazol, Marital Status and Occupational Status were insignificant in neither 
adjusted nor independent analysis. 
Table: 4.3: Independent Semi-Parametric Analysis of Covariates Effect (Cox PH Model) 
Covariates  Coefficients SE Wald P-Value Hazard Ratio 
Age .014 .004 10.503 .001 1.014 
Gender .223 .088 6.398 .011 1.250 
Functional Status 
  
74.849 .000 
 
Functional Status(1) .666 .095 49.054 .000 1.947 
Functional Status(2) .962 .135 50.784 .000 2.616 
Weight -.016 .004 13.756 .000 .984 
WHO Clinical Stage 
  
297.854 .000 
 
WHO Clinical Stage(1) .970 .737 1.729 .188 2.637 
WHO Clinical Stage(2) 1.350 .710 3.613 .057 3.858 
WHO Clinical Stage(3) 2.811 .710 15.680 .000 16.626 
CD4Percent 
  
25.654 .000 
 
CD4Percent(1) -.865 .171 25.643 .000 .421 
CD4Percent(2) -11.135 106.067 .011 .916 .000 
Cotrimoxazol -.191 .117 2.688 .101 .826 
TB Status .868 .192 20.394 .000 2.383 
Marital Status 
  
1.209 .546 
 
Marital Status(1) .106 .097 1.200 .273 1.112 
Marital Status(2) -8.937 95.857 .009 .926 .000 
Education -.229 .088 6.769 .009 .795 
Occupation -.186 .381 .237 .626 .831 
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Opportunistic Infections 2.138 .712 9.014 .003 8.485 
Risk Behavior 1.055 .411 6.580 .010 2.872 
Household Size .070 .027 6.883 .009 1.072 
Adjusted effect of covariates was then estimated by multi-factor analysis of Cox PH 
model after identifying potential risk factors. However, some factors which were 
significant in the independent analysis appeared to be insignificant in the multi-factor 
analysis due to relative importance.  
As a result, best possible combination of significant covariates (factors) was selected to 
fit the desired model by using Strategy For Model Selection described in Section3.2.4.1. 
In this particular case, stepwise Forward Selection and Backward Elimination of 
covariates were performed on the basis of Wald Test in such a way that variables 
predicted as significant by Non-Parametric analysis had 5% chance to be included in the 
model and a probability of 0.1 for exclusion. Exclusion of Covariates from a model when 
they were significant in the independent analysis is to mean, inclusion of such factor will 
add no further expression of variation in survival time or function of it than already 
expressed by the included covariates since the presence of association among covariates 
might be reason for such removal. Although conditional selection of covariates is also 
possible based on interest or biological importance, such procedure has not been used in 
this particular study since the main purpose was to compare Cox PH and AFT models in 
determining factors related to survival time of HIV/AIDS patients. However, minimizing 
uncertainty associated with effects of some factors was taken as specific objective of this 
study. Therefore, stepwise selection of a set of significant variables that results in 
minimum likelihoodlog2  (for comparison of nested models) and AIC  (for 
comparison of other alternative models) was performed to fit the final model. (See 
variable selection procedures in Section 3.2.4.1).  
Therefore, after Household Size (P-Value= 0.768) and Education (P-Value= 0.5313) 
excluded by stepwise Backward Elimination procedure at 10% level of significance 
(probability of removal), WHO clinical Stage, CD4 Percent and TB Status were selected 
to be included in the Cox PH model at 5% level of significance as the most significant 
factors affecting survival of HIV/AIDS patients with P-Value=0.000. Similarly, Age (P-
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Value=0.0047), Functional Status (P-Value=0.0163), Opportunistic Infections (P-
Value=0.0285) and Risk Behavior (P-Value=0.0317) were also statistically significant in 
the Stepwise Forward Selection procedure. On the other hand, Gender and Weight were 
removed from the model since they were not selected by stepwise forward procedure and 
inclusion of both/any of these covariates couldn‘t results in much decrease in statistical 
information criterion statistics, although they were not removed by Stepwise Backward 
Elimination procedures. Hence, the final Cox PH model was fitted only for selected 
significant covariates by Stepwise Forward procedure based on results in Table: 4.4. 
Table: 4.4: Adjusted Semi-Parametric Analysis of Covariates Effect (Cox PH Model) 
Covariates 
 
Categories Coeff. SE P-
Value 
Haz. 
Ratio 
95% CI for Haz. 
Ratio 
 LL UL 
WHO Clinical 
Stage 
 
I Ref.   1   
II 1.008 .737 .172 2.740 .65 11.623 
III 1.332 .711 .061 3.789 .94 15.263 
IV 2.684 .712 .000 14.64 3.63 59.060 
CD4Percent 
 
12-15% Ref.   1   
16-28% -.660 .172 .000 .517 .37 .724 
Above28% -10.68 105.62 .919 .000 .00 1.828E+085 
TB Status 
 
Negative Ref.   1   
Positive .760 .196 .000 2.139 1.458 3.137 
Functional Status 
 
Working Ref.   1   
Ambulatory .302 .099 .002 1.353 1.115 1.643 
Bedridden .221 .143 .122 1.247 .943 1.650 
Opportunistic 
Infections 
 
No Ref.   1   
Yes 1.510 .726 .038 4.525 1.091 18.770 
Risk Behavior 
 
No Ref.   1   
Yes .964 .421 .022 2.621 1.150 5.976 
Age  .010 .005 .038 1.010 1.001 1.019 
In Cox PH model analysis, a coefficient associated with continuous covariate is a change 
in the log hazard ratio due to a unit increase in the value of the variable under 
consideration holding the value of other covariates constant. The corresponding Hazard 
Ratio can be obtained by exponentiation of the coefficient and it is an adjusted 
multiplicative effect on hazards of death for a unit change in the covariate value. 
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Similarly, a coefficient associated with a particular category of a categorical covariate is 
adjusted additive effect on log hazard ratio for change of level from reference to that 
particular category of the covariate. The corresponding hazard ratio is a multiplicative 
effect on hazard of death for such change in levels of covariates holding the effects of 
other covariates constant. 95% CI for hazard ratio including the value 1 shows that 
statistical non-significance; 95% CI which does not include the value 1 shows statistical 
significance at 5% level of significance (Section3.2.4.1). 
Consequently, the multiple-Covariates Cox PH model was then fitted to predict the effect 
of significant covariates in such a way that 1k dummy variables have been created for 
categorical covariates having k levels so that one of the categories of each covariate was 
taken as a reference. The first category of each categorical covariate has been taken as a 
reference in this particular case. Categorical predictor WHO Clinical Stage had four 
levels and hence, three dummy variables ( iii WHOCSWHOCSWHOCS 432 , , ) have been 
created to include this predictor in the model taking WHO Clinical Stage I as reference 
group. Similarly, CD4 percent had three categories and included by ( ii CDCD 32 4 ,4 ) 
taking CD4% of 12-15% as reference; each of the categorical predictors TB Status, 
Opportunistic Infections and Risk Behavior had two levels and therefore, included as 
iii RBOITB 222  and  ,  by taking TB Status negative, Opportunistic Infections no and Risk 
Behavior no as reference respectively; Functional status had three categories and 
therefore included as ( ii FSFS 32  , ) and working as reference. After a multiple covariate 
model of main effects has been built, then predictors were checked for all possible 
interactions and none of the interactions were statistically significant. Age is continuous 
covariate. Hence, no need to create dummy variables for such covariates and it was 
included as iAGE . The final multifactor Cox PH model based on Table: 4.4 is then given 
by 
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Once a model has been fitted, there are a number of aspects of the fit of model that need 
to be studied since model checking is essential part of modeling. Hence, the adequacy of 
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the fitted model, including the PH assumption and the goodness of fit, was assessed by 
different diagnostic procedures (See Model Diagnostics for Cox PH Model in section 
3.2.4.1). After the values of continuous covariate Age was grouped to give categorical 
variables, all covariates have been checked for PH assumption by using plot of 
  Survivalloglog   against survival time (Section 3.2.4.2). This plot was roughly 
parallel for separate groups of patients defined by categories of most covariate. However, 
there was a little reason to doubt the proportional hazards assumption since there were 
some covariates which seems to have levels associated with plots that are not in line with 
others (See Figure7. 2 in the Appendix). 
Although such impression results from relatively high cumulative hazard estimates at the 
longest survival times experienced by patients in that group, these plots take no account 
of the values of other variables and it could be that the survival times of the individuals in 
such groups have been affected by the values of other variables. Therefore, other 
approaches have been also used to certain conclusions. Interactions of the predictors and 
survival time were included in the model as Time-dependent covariates. There were no 
evidences that the PH assumption was violated for any of the predictors and it could be 
noted that covariates became insignificant when the interactions were comprised in the 
model (Table: 4.5). Likewise, Schoenfeld residuals were used to check the PH assumption 
separately for each covariate. The p-values for testing whether the correlation between 
Schoenfeld residuals for each covariate and ranked survival time were all greater than 
0.05 except Age for which P-Value=0.0442, which suggested that the PH assumption was 
plausibly satisfied for all covariates but Age (Appendix, Table7. 2), although the 
interaction of Age with time was insignificant (Table: 4.5). Consequently, the PH 
assumption for Age needs to be further assessed. Since it is a continuous covariate, 
Scaled Schoenfeld residuals for age was plotted against rank of survival time and it 
suggested that the PH assumption was not violated that much (Appendix, Figure7. 3). 
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Table: 4.5: Statistical Test for PH Assumptions by Adding Time Varying covariates in to 
Cox PH Model 
Effects of Covariates _t Haz. Ratio P>z [95% 
Conf. 
Interval] 
Main  WHO Clinical Stage     
II 11.250 0.130 0.684 74.161 
III 55.589 0.054 0.688 737.983 
IV 779.129 0.051 0.362 1352.506 
CD4Percent     
16-28% 1.989 0.558 0.200 19.792 
Above28% 0.000 1.000 0.000 . 
TB Status 1.906 0.596 0.175 20.714 
Functional Status     
Ambulatory 0.710 0.471 0.280 1.801 
Bedridden 0.341 0.258 0.053 2.202 
Opportunistic Infections 9.1e+303 . . . 
Risk Behavior 117.062 0.116 0.308 44460.756 
Age 0.946 0.103 0.886 1.011 
Interaction of covariates with 
time t  
Age 1.001 0.052 1.000 1.001 
Functional Status 1.007 0.164 0.997 1.017 
WHO Clinical Stage 0.986 0.060 0.975 0.998 
CD4Percent 0.985 0.252 0.961 1.011 
TB Status 1.001 0.932 0.975 1.027 
Opportunistic Infections 0.003 1.000 0.000 . 
Risk Behavior 0.961 0.190 0.904 1.020 
After checking the PH assumption, Goodness of fit of Cox PH model to the dataset was 
assessed by residual plots. A plot of the Cox-Snell residuals against the cumulative 
hazard of Cox-Snell residuals also known as cumulative hazard plot of Cox-Snell 
residuals was one of the methods used in such diagnostics by residual plots. Hence, the 
plotted points in (Figure: 4.2) are fairly close to a straight line through the origin, which 
has approximately unit slope. i.e., the plots seem to have no symmetric departure from a 
straight line. This suggested that the model fitted to the dataset was seems to be 
satisfactory. However, a model that fits the dataset needs to be searched since the plots 
are not perfectly straight line suggesting that further aspects of the model has to be 
assessed. 
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Figure: 4.2: A Cumulative Hazard Plot of Cox-Snell Residuals 
Although plot in Figure: 4.2 could help to infer that the Cox PH model fitted to the entire 
dataset was reasonable, further inspections from different aspects needed to be made in 
order to increase firmness of the conclusion. As a result, the plot of deviance residuals 
against the risk scores was used to have information about whether there were patients 
that might be expected to survive for a short or long time than predicted by the fitted 
model. Figure: 4.3 shows that the distribution of Risk Score plot of Deviance residuals 
seems to be approximately symmetrical about zero. This indicates that there are no 
outlying observations. However, some individuals appear to have smaller value of 
deviance residual associated with larger risk score (i.e., some individuals seem to survive 
longer than expected).  
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Figure: 4.3: Plot of the Deviance Residuals against the Values of Risk Score 
Hence, Delta-Beta (DFBETA) statistics was used to measure the estimated change in 
coefficients as results of removal of a case since the adequacy of the fitted Cox PH Model 
needed some reassurance. Index plots of DFBETA statistics for all indicator variables in 
the Cox PH model were used to detect expected influential observations (Appendix, 
Figure7. 1). Eventually, on the basis of their standard errors, it has been noted that 
Coefficients did not change too much when the observations corresponding to the largest 
Delta-Beta statistics were removed. i.e., magnitudes of all Delta-Beta statistics were less 
than the corresponding standard error of coefficients (See Table: 4.6). As a result, such 
observations were not excluded from the dataset and final conclusion was reached to be 
there were no influential observations in the dataset.  
Table: 4.6: Detecting Expected Outliers by Magnitudes of DFBETA Statistics 
Indicators Expected outlier Index DFBETA  )(se  
Stage I Reference 0.000000  
Stage II 2929 0.4992054 0.7373557 
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Stage III 2929 0.4981006 0.7108191 
Stage IV 2929 0.4982148 0.7117566 
CD4%: 12-15% Reference 0.000000  
CD4%: 16-28% 1605 0.039314 0.1719676 
CD4%: Above 28% 1375 0.2228134 2.09e+08 
FS: Working Reference 0.000000  
FS: Ambulatory 2120 0.0113839 0.0989787 
FS: Bedridden 1380 0.0338106 0.1428324 
TB: Negative Reference 0.000000  
TB: Positive 2684 0.0368193 0.1955617 
RB: No Reference 0.000000  
RB: Yes 108 0.1685705 0.4205107 
OIs: No Reference 0.000000  
OIs: Yes 1827 0.4050735 .7258408 
Age 219 0.001903 0.0046558 
Furthermore, the continuous covariate Age was checked whether the correct functional 
form was adopted in the model in order to assess linearity assumption. The Martingale 
Residual obtained for the fitted Cox PH Model excluding Age was Plotted against the 
values of Age along with a LOWESS smooth curve (Figure: 4.4). There was no definite 
pattern in the scatter plots but the smoothed curve deviates from a horizontal line. This 
indicated that there is a need other than a linear term in age. Thus, the effect of age 
wasn‘t linear in the Cox PH Model fitted to the dataset.  
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Figure: 4.4: Plot of Martingale Residual against the Values of Age Along with a 
LOWESS Curve 
4.4. AFT Models 
The accelerated failure time (AFT) model is another alternative of the Cox PH model 
when assumptions in the Cox PH are violated. In this particular study, the dataset was 
fitted using Exponential, Weibull, Log-Logistic, Log-Normal and Generalized Gamma 
AFT models. In each case, Distribution based stepwise variable selection procedure has 
been used to identify a set of potential risk factors among covariates that have been 
significant by the Non-Parametric analysis which results in a good fit of a particular type 
of AFT Model. As a result, models have been built to possibly minimize loss of 
information due to exclusion of significant covariates. So that comparison of models on 
the basis of the dataset will be unbiased. Both independent and multiple covariate 
analysis were implemented. In the independent analysis, similar conclusions could be 
made about the effect of individual covariates as it was in the Cox PH model. However, 
fitted AFT Models seem to provide more information as compared to the fitted Cox PH 
model since they have additional covariates except Exponential AFT Model. This might 
-3
-2
-1
0
1
m
a
rt
in
g
a
le
 r
e
si
d
u
a
l
0 20 40 60 80 100
Age
bandwidth = .8
Lowess smoother
 71 
 
be an indication that AFT Models could be able to identify more factors than Cox PH 
Model, even if inference is better to made based on statistical criteria (See Table: 4.7).  
Although intensive differences have not been examined in estimates of all models and 
number of covariates were the same in AFT models, possible combination of covariates 
were different to fit Exponential Regression Model in AFT form. By Stepwise 
procedures, the continuous covariate Weight was added to all AFT Models over 
covariates that had been already fitted to Cox PH Model. However, Opportunistic 
Infections was excluded from Exponential AFT Model instead, Gender has been included 
to minimize loss of information. As it was in Cox PH Model, Educational Status was not 
included in any of AFT Models. No interactions were statistically significant in multiple-
covariates AFT models. The results from the different AFT models applied to ART 
dataset are presented in Table: 4.7 and spaces corresponding to covariates which were 
significant in independent analysis but not selected by stepwise procedure to fit a 
particular type of AFT Model are shaded. 
As a first step to examine Whether an AFT model confer a good fit of the dataset, the Q-
Q plot was used for covariates having two categories. The resulting plots approximates 
well to a straight line from the origin indicating that the AFT model may stipulate an 
appropriate Model, although there were some plots seem to be far from straight line 
(Appendix, Figure7. 5).  
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Table: 4.7 : Multiple-Covariates Analysis: AFT Models 
Covariate
s 
Exponential Weibull Log-Logistic Log-Normal  Generalized Gamma  
  p  95%CI   p  95%CI   p  95%CI   p  95%CI   p  95%CI 
const 10.69 0.00 9.04 12.3 5.37 0.00 5.13 5.62 5.32 0.00 5.09 5.55 5.33 0.00 5.11 5.54 5.35 0.00 5.12 5.58 
Age -0.01 0.02 -0.02 -0.001 -.001 0.02 -.003 -.0002 -.001 0.03 -.003 -.0001 -.001 .04 -.003 -.0001 -.001 0.02 -.003 -.0002 
Gender -0.20 0.04 -0.40 -0.01                 
Functional Status (Reference: Working) 
Ambulatory -0.32 0.00 -0.52 -0.12 -0.03 0.01 -0.06 -0.01 -0.04 0.01 -0.06 -0.01 -0.04 0.01 -0.07 -0.01 -0.03 0.01 -0.06 -0.01 
Bedridden -0.32 0.03 -0.61 -0.04 -0.02 0.31 -0.05 0.02 -0.02 0.28 -0.06 0.02 -0.03 0.20 -0.07 0.01 -0.02 0.25 -0.06 0.02 
Weight 0.01 0.02 0.00 0.03 .001 .04 .0001 .003 .001 0.04 .0001 .003 .002 .03 .0001 .003 .001 0.04 .00008 .003 
WHO Clinical Stage (Reference: I) 
II -1.12 0.13 -2.57 0.33 -0.12 0.21 -0.30 0.07 -0.10 0.23 -0.26 0.06 -0.07 0.32 -0.19 0.06 -0.09 0.24 -0.25 0.06 
III -1.71 0.02 -3.10 -0.31 -0.16 0.08 -0.33 0.02 -0.13 0.09 -0.29 0.02 -0.09 0.16 -0.21 0.03 -0.13 0.10 -0.28 0.02 
IV -2.84 0.00 -4.24 -1.44 -0.32 0.00 -0.50 -0.15 -0.32 0.00 -0.47 -0.16 -0.28 0.00 -0.41 -0.16 -0.31 0.00 -0.46 -0.16 
CD4 Percent (Reference: 12-15%) 
16-28% 0.75 0.00 0.41 1.09 0.08 0.00 0.04 0.13 0.08 0.00 0.04 0.12 0.08 0.00 0.04 0.12 0.08 0.00 0.04 0.12 
Above28% 14.57 0.99 -1548 1577 1.75 0.98 -127 131 1.59 0.98 -148.9 152 1.05 0.98 -95.1 97.2 1.49 0.99 -188.6 191.6 
TB Status (Reference: Negative) 
Positive -1.11 0.00 -1.48 -0.74 -0.09 0.00 -0.14 -0.04 -0.09 0.00 -0.14 -0.05 -0.09 0.00 -0.14 -0.05 -0.09 0.00 -0.14 -0.05 
Education (Reference: Educated) 
Not 
Educated 
                    
OIs (Reference: No) 
Yes     -0.17 0.01 -0.30 -0.04 -0.19 0.00 -0.31 -0.07 -0.22 0.00 -0.35 -0.08 -0.19 0.00 -0.32 -0.06 
RB (Reference: No) 
Yes -1.57 0.00 -2.44 -0.70 -0.12 0.02 -0.23 -0.02 -0.12 0.02 -0.23 -0.02 -0.13 0.01 -0.23 -0.03 -0.13 0.02 -0.23 -0.02 
/ln_p     2.08 0.00 2.02 2.15             
p     8.03  7.51 8.59             
1/p     0.12  0.12 0.13             
/ln_gam         -2.2  -2.3 -2.2         
gamma         0.11  0.10 0.11         
/ln_sig             -1.59 0.00 -1.65 -1.53 -1.84 0.00 -1.98 -1.71 
/kappa                 0.55 0.00 0.31 0.79 
sigma             0.20  0.19 0.22 0.16  0.14 0.18 
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In similar manner with the Cox PH Model, a continuous covariate with a positive 
coefficient prolongs survival time of HIV/AIDS patient as its value increases. Similarly, 
level of categorical covariate or an indicator with a positive coefficient is associated with 
longer survival time of patients as compared to the corresponding reference. On the other 
hand, covariates/indicators with negative coefficients are associated with accelerated 
death time as they increase or as they compared to the corresponding references.  
Although it would be easy to transform estimated coefficients from PH metric of 
Exponential and Weibull to their AFT metric by changing the sign of coefficients from 
Exponential PH and multiplying coefficients from Weibull PH by ancillary parameter 
p
1 respectively, results of multiple covariate analysis based on stepwise procedure 
using Exponential and Weibull have been presented in both metrics (See Appendix, 
Table: 7. 3 for PH metric and Table: 4.7 for AFT metric). Nevertheless, the values of 
statistical information criteria statistics were the same for AFT and PH form of the model 
while either of the two distributions was assumed for analysis. Hence, information 
criteria statistics presented in Table: 4.8 represents not only AFT from of these two but 
also their PH form as well (See next section). 
4.5. Results of Model Comparison 
After finding best possible combination of covariates that are assumed to explain the 
entire dataset with minimum loss of information on the basis of each Model, the 
performance of models was compared using both l2  and AIC. The l2 was used to 
compare nested models whereas AIC was used to compare non-nested models. 
Accordingly, Age, Functional Status, Weight, WHO Clinical Stage, CD4 Percent, TB 
Status, Opportunistic Infections and Risk Behavior yield the minimum possible loss of 
information for all parametric models except Exponential AFT Model in which Gender 
was included instead of Opportunistic Infections (See Table: 4.7).  
Intending to find out the best model for the dataset, Statistical Information Criteria 
Statistics (. l2 and AIC ) were computed for all Models considered in this study (Table: 
4.8). According to the statistics, it could be noted that loss in information reduces as a 
covariate added to a particular type of model in a stepwise manner. However, the amount 
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by which the loss reduces does depend on the importance of the covariate being added to 
the model. The results in Table: 4.8 are therefore presented to make within and between 
comparison of PH and AFT Models for nested as well as non-nested. Despite, all possible 
combination of covariates were not fitted. Instead, combination of covariates which 
thought to be best on the basis of model type specific stepwise procedures since fitting 
model would add no value and is not statistically meaningful but time consuming. 
As a result, Information Criteria Statistics were handled for Cox and Gompertz (as PH 
Model); Exponential and Weibull (as PH and AFT Model); Log-Logistic, Log-Normal 
and Generalized Gamma (as AFT Model), starting from null to final models (Table: 4.8).  
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Table: 4.8: Statistical Information Criteria for Comparison of Models by Stepwise Selected Covariates for Possible Reduction of Loss 
of Information 
Stepwise Covariate 
Selection 
As PH Models Only As Both PH and AFT Models As AFT Models Only 
Cox Gompertz Exponential Weibull Log-Logistic Log-Normal Generalized 
Gamma 
l2  AIC
 
l2
 
AIC
 
l2
 
AIC
 
l2
 
AIC
 
l2
 
AIC
 
l2  AIC
 
l2
 
AIC
 
Null 7217.2 7217.2 1282.8 1286.8 2845.1 2847.1 1228.2 1232.2 1212.0 1215.6 1209.9 1213.9 1207.5 1213.5 
WHO Clinical Stage 6931.6 6937.6 975.8 985.8 2562.4 2570.4 930.2 940.2 915.0 925.0 925.2 935.2 911.7 923.7 
CD4 Percent 6901.8 6909.8 943.9 957.9 2520.8 2532.8 898.5 912.5 884.7 898.7 896.3 910.3 881.2 897.2   
TB Status 6872.8 6882.8 896.2 912.2 2467.3 2481.3 860.4 876.4 855.2 871.2 869.7 885.7 849.3 867.3 
Age 6865.3 6877.3 889.9 907.9 2450.1 2466.1 853.7 871.7 849.7 867.7 864.3 882.3 843.1 863.1 
Functional Status 6857.2 6875.2 881.4 903.4 2434.4 2454.4 845.9 867.9 840.2 862.2 854.1 876.1 834.3 858.3 
Opportunistic Infections  6850.2 6868.2 863.5 887.5   834.4 858.4 827.5 851.5 841.9 865.9 822.3 848.3 
Risk Behavior 6843.1 6863.1 857.2 883.2 2421.3 2443.3 828.5 854.5 822.0 848.0 836.2 862.2 816.6 844.6 
Weight   852.6 880.6 2418.0 2442.0 824.3 852.3 817.9 845.9 831.7 859.7 812.3 842.3 
Gender     2413.6 2439.6         
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Therefore, based on the results in Table: 4.8, all models were compared using Statistical 
Information Criteria ( AIC and l2 ) for stepwise selected covariates. Since we had a 
little concern about the fit of Cox PH Model, all parametric models appeared to fit better 
than Cox PH. Being nested with in Gamma Model, the Exponential, Weibull, and Log-
Normal models were compared using the statistic l2 . Hence, starting from null to 
adding the third covariate step wise, the Log-Normal model appeared with the minimum 
statistic and seemed to fit better. But the Weibull Model fitted the dataset better since it is 
associated with minimum statistic at the final step. However, the statistic l2  is not 
valid for comparing models that are not nested. In such case, the statistic AIC was used to 
compare the models. Although, the Log-Logistic Model is not nested in Gamma, it was 
better than Weibull. The Gompertz Model provided better fit as compared to Cox PH and 
Exponential Models.  
As a final point, Generalized Gamma Model appeared to be an appropriate AFT model 
according to AIC compared with other models, although it is only slightly better than 
Log-Logistic and Weibull (as PH and AFT)  models. It has also been noted that the Cox 
PH and Exponential (as PH and AFT) models were poorer fits according to Information 
Criteria Statistics suggesting that assuming exponential distribution for the data set would 
be highly misleading. Thus, this provided more evidence that could strengthen the doubt 
on PH assumption since the 1
st
 (Gamma) and 2
nd
 (Log-Logistic) best Models were AFT 
form rather than PH. 
After identifying the best model in identifying factors affecting the survival of HIV/AIDS 
patients under ART follow-up, the goodness of fit of the model was checked using 
residual plots. The cumulative hazard plot of the Cox-Snell residuals in Generalized 
Gamma model is presented in Figure: 4.5. The plotted points lie on a line that has a unit 
slope and zero intercept. So there was no reason to doubt the suitability of this fitted 
Generalized Gamma model. Eventually, the conclusion appeared to be the Generalized 
Gamma model was the best and perfect fitting AFT model based on AIC criteria and 
residuals plot. 
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Figure: 4.5: Cumulative Hazard Plot of the Cox-Snell Residual for Generalized Gamma 
AFT Model 
The best fitting survival model for the dataset is Generalized Gamma AFT Model. 
Henceforth, the effect of covariates will be interpreted in terms of Time Ratios based on 
the best fitted model in order to understand it in easier way. In STATA, the Reporting 
option, tr specifies that exponentiated coefficients, which are interpreted as time ratios 
and it is appropriate only for the Log-Logistic, Log-Normal, and Gamma models, or for 
the Exponential and Weibull models when fit in the accelerated failure-time metric (tr 
may be specified at estimation or upon replay). Therefore, Time Ratios associated with 
selected significant covariates that represented the entire dataset on the basis of 
Generalized Gamma AFT Model are presented in Table: 4.9 and the corresponding 
coefficients are presented in Table: 4.7 together with other models considered in the 
study. 
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Table: 4.9: Time Ratios on the Basis of Generalized Gamma AFT Model 
Covariates Tm. Ratio Std. Err. Z P>z [95% Conf. Interval] 
 
Age .999 .001 -2.28 0.02 .997 .9998 
Functional Status ( Reference: Working with time ratio=1) 
Ambulatory .966 .013 -2.61 0.01 .941 .9914 
Bedridden .977 .020 -1.16 0.25 .940 1.016 
Weight 1.0014 .001 2.07 0.04 1.0001 1.003 
WHO Clinical Stage ( Reference: I with time ratio=1) 
II .911 .072 -1.18 0.24 .780 1.064 
III .882 .067 -1.65 0.10 .759 1.024 
IV .734 .056 -4.02 0.00 .632 .8534 
CD4 Percent( Reference: 12-15% with time ratio=1) 
16-28% 1.084 .023 3.81 0.00 1.040 1.1297 
Above28% 4.448 431.4 0.02 0.99 1.25e-82 1.58e+83 
TB Status( Reference: Negative with time ratio=1) 
Positive .912 .022 -3.86 0.00 .870 .9555 
Opportunistic Infections( Reference: No with time ratio=1) 
Yes .826 .055 -2.85 0.00 .725 .9420 
Risk Behavior( Reference: No with time ratio=1) 
Yes .882 .046 -2.39 0.02 .796 .9776 
_cons 211.4 24.9 45.40 0.00 167.8 266.4 
/ln_sig -1.844 .0705 -26.15 0.00 -1.982 -1.705 
/kappa .552 .122 4.54 0.00 .314 .7907 
Sigma .158 .0112   .138 .1817 
Under the Generalized Gamma AFT model, the estimated acceleration factor for a year 
increase in age considering the effect of other covariates in the model constant was 0.999 
with 95%CI: [0.997, 0.9998], which indicates that older patients were more likely to die 
earlier than patients who were relatively younger. In similar fashion, it was 1.0014; 
95%CI: [1.0001, 1.003], for a Kg increase in weight providing an evidence that patients 
with relatively larger weights were more likely to survive as compared to patients with 
relatively smaller Weights (Table: 4.9). The corresponding coefficients can also be 
interpreted as additive effects on the Natural Log of survival time due to a unit increase in 
that particular continuous covariate in question holding the effects of other covariates 
constant (Table: 4.7). 
Analogously, the estimated acceleration factors for Ambulatory and Bedridden patients 
were 0.966; 95%CI: [0.941, 0.9914], and 0.977; 95%CI: [0.940, 1.016], respectively as 
compared to working patients suggesting that the survival time of working patients was 
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longer than patients with functional status Ambulatory and Bedridden. However, the 
indicator associated with Bedridden was insignificant (Table: 4.9). In terms of 
coefficients, the Natural Log of survival times for Ambulatory and bedridden patients 
decrease by 0.03 and 0.02 respectively as compared to the Natural Log of survival times 
for working patients
2
. Furthermore, WHO Clinical Stage was also one of the significant 
covariates with acceleration factor 0.911; 95%CI: [0.780, 1.064], 0.882; 95%CI: [0.759, 
1.024] and 0.734; 95%CI: [0.632, 8.534] for Stage II, III and IV patients respectively. 
This indicates that although Stage II and III were not significant, patients with higher 
WHO Clinical Stages were less likely to survive longer as compared to that of with Stage 
I. It has also been noted that, patients with CD4 percent between 16 and 28 significantly 
survived longer than patients having CD4 percent between 12 and 15 with estimated 
acceleration factor 1.084. The estimated median survival time for patients having CD4 
percent above 28 was 4.448 times that of patients having CD4 percent between 12 and 
15.  However, it was not significant due to absence of recorded death event in that group 
(Table: 4.9). 
Not only these, but also being TB positive was one of significant factors that shortened 
the life span of HIV patients. According to the results in Table: 4.7, estimated average 
survival time of TB positive patients under Natural logarithm was less by 0.09 as 
compared to TB negative patients. In other words, being TB positive was associated with 
accelerated death time with estimated acceleration factor 0.912 indicating that TB 
Positive patients have approximately 9% less average survival time than TB Negative 
patients. Likewise, the estimated acceleration factor for patients having any kind of risk 
behavior was 0.882 and it was 0.826 for patients with any opportunistic infection (Table: 
4.9). This was evidence that having risk behavior or opportunistic infection lets patients 
die earlier than patients who do not have any risky behavior or opportunistic infections. 
The decreases in the natural logarithm of survival time were 0.13 (patients with risky 
behavior) and 0.19 (patients having OIs) as compared to patients with no risky behavior 
and patients do not have OIs respectively (Table: 4.7). 
                                                          
2
 Note that, the effect of a particular concomitant factor on Patients Survival from a model fitted to more 
than one covariate is interpreted by considering the effects of the rest covariates in the model as constant. 
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Now, Model based predictions need to be derived and from equation [3.55], the time ratio 
or median survival time for a particular patient ( thi individual) with authentic baseline 
values of selected covariates relative to the median survival time computed from baseline 
survivor function which takes zero (reference) values of all covariates under the 
Generalized Gamma model is given by 
 














ii
iiiii
iiiii
iGG
RBOIs
TBSCDCDWHOCSWHOCS
WHOCSWEIGHTFSFSAGE
TR
11
12132
121
13.019.0
09.0449.1408.031.013.0
09.001.002.003.0001.0
exp50
 
Hence, the relative median survival time for an individual patient can be predicted with 
the help of this model. 
Note that, the shape parameter k ( kappa) tested whether it is significantly different zero 
and one to check the appropriateness of Log-Normal and Weibull AFT Models 
respectively. The corresponding Wald tests provided that the shape parameter is 
significantly different from zero and one as well. From Table: 4.7, the 95% CI for k was 
[0.31, 0.79] with 000.0 valuep indicating that the Log-Normal AFT model is not 
appropriate. Similarly, after fitting the full Generalized Gamma AFT Model, the 
command (test [kappa]_cons=1) in STATA resulted in Chi-Squared value of 13.55 with 
1 degree of freedom and 0002.0 valuep suggesting that the Weibull AFT Model 
was not appropriate model for the dataset. Hence, the Generalized Gamma AFT model 
that allows variety of shapes of the hazard function through time was the best fit to the 
dataset in every aspect of model comparison since the change in hazard was not 
monotonic over time. 
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4.6. Discussion  
The two often-used models for adjusting survivor functions for the effects of covariates 
are the accelerated failure-time (AFT) model and the multiplicative or proportional 
hazards (PH) model. However, Cox PH Model probably seems to be interest of most 
medical researchers than the AFT metric in which survival time is assumed to follow a 
particular distribution. In using the Cox PH Model, proportional hazards assumption 
needs to be satisfied to make trustworthy inference from a particular dataset. But the PH 
assumption may be violated for some reason based on the nature of the dataset. Although 
adding time dependent covariates and taking the covariate associated with violence of PH 
assumption as stratification id variable (often for categorical covariates) are solutions, in 
such case, AFT Model is more informative and the best alternative to use since it can 
provide precise estimates if distributional assumption satisfied. Moreover, interpretation 
of covariates effect from AFT Model is directly associated with average survival times 
unlike Cox PH Model in which estimates are interpreted as multiplicative effect on 
hazards.  
The parametric distributions Exponential, Weibull, Gompertz, Log-Logistic, Log-Normal 
and Generalized Gamma are most commonly encountered in survival analysis and are 
currently supported by software like STATA. Exponential and Weibull distributions can 
be used in both metric. However, the Gompertz distribution is applicable only in PH 
metric whereas the rest in AFT metric only. As a result, some studies were found to be 
conducted on comparison of the two metric. However, inconsistencies arisen in decisions 
made on appraisal from different datasets.  This is probably due to the nature of the event 
that generates the time. In spite of this, model wise variable selection procedures need to 
be performed that might be responsible for different set of covariates. But most studies 
conducted regardless of model wise selection procedures (See [34], [45]). In such case, 
statistical information criteria for a particular model containing insignificant covariate (s) 
will be inappropriately large if there are covariates in the dataset that can be significantly 
fitted by the model. Hence, the model on the basis of which the selection procedure is 
made will be favored to represent the data set unbecomingly and misleading conclusion 
will be made on appraisal. In fact, it is one of the problems that revived this study.   
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Although there were studies with a final conclusion that the Cox PH Model provided a 
better fit than AFT Models [11], according to conclusions made by most of the 
researchers, it is customary that AFT models were best based on statistical criteria (See 
section 2.2.2). In studies conducted in PH metric, The Gompertz distribution is relatively 
less used. In contrast, Exponential and Weibull models were found to be more used and 
likely to fit a particular dataset than Cox PH Model (See [41] and [57]). Log-Logistic 
AFT Model was frequently chosen over the other when comparison between the two 
metric is considered.  However, Log-Normal and Generalized Gamma AFT Models were 
also preferred by some researchers on the basis of information criteria. 
In this particular study, the Generalized Gamma AFT Model was the best model in 
determining maximum possible number of factors affecting the survival of HIV/AIDS 
patients under ART follow-up with relatively minimum loss of information. Fittingly, 
patients‘ WHO Clinical Stage, CD4 Percent, TB Status, Functional Status, Age, Risk 
Behavior, Weight and Opportunistic Infections were identified to have significant effect 
on survival time of HIV patients. The Logistic frame work and Cox PH models were 
often used methods in determining such factors (See section 2.2.1). Yet, survival analysis 
is more appropriate for such inquiry preferably, the AFT metric. Since availability of 
software packages made it easy to choose the most appropriate model from obtainable 
survival models, we don‘t need prior assumption regarding specific type of distribution 
for event times instead, analyzing the data by using a model with significantly minimum 
information criteria statistic. Therefore, inference could be made in easily understandable 
and sensible way besides get hold of more precise and reliable estimates of effects. 
Consequently, there will probably high chance of minimizing contradictions on 
conclusions made from different researchers on a particular area.  
As specific aim of the study, the effect Age, Gender and Level of Education was tried to 
be assessed to get better confidence to wards inference on their effect. Although they 
were all significant independently, Age was the only significant factor in multiple-
covariates analysis. Hence, in the presence of other significant covariates considered in 
the study, the conviction that Gender and Level of Education don‘t significantly affect the 
survival of HIV patients but Age is strengthened. This was true for all parametric Models 
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the explored the same set of covariates except Exponential regression Models that have 
relatively high information criteria statistics as compared to the other parametric models.
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5. Conclusions and Recommendations 
5.1. Conclusions 
Despite the challenges, this study was conducted to investigate the effects of socio-
economic, demographic and health factors on survival of HIV/AIDS patients. According 
to information criteria statistics ( AIC and l2 ), the Generalized Gamma AFT model best 
described the dataset on a large number of patients from University of Gondar teaching 
Hospital. Using stepwise selection procedures for Generalized Gamma AFT model, 
WHO Clinical Stage, CD4 Percent, TB Status, Functional Status, Age, Risk Behavior, 
Weight and Opportunistic Infections were fitted as best possible combination of 
covariates, although Gender and Level of Education were ascertained to be potential risk 
factors by Non-Parametric as well as independent survival analysis. On the other hand, 
Marital Status Occupational Status and Cotrimoxazol were insignificant at 5% level of 
significant by Non-Parametric analysis. Hence, the stepwise procedures were performed 
with chance of 10% exclusion and 5% inclusion from/to a model for only 10 covariates 
known to be significant by Non-Parametric or independent analysis. According to the 
multiple-covariates analysis of the best fitted model, the study revealed that advanced 
WHO clinical stages (III and IV), lower CD4 percent (12-15%), TB co-infection, being 
bedridden or ambulatory functional status, being relatively old in age, having relatively 
lower weight, the presence of Opportunistic Infections and Risky Behaviors were 
strongly related to relatively minimum average survival time or accelerated death time. 
Furthermore, Log-Logistic, Weibull, Log-Normal and Gompertz regression models were 
the 2
nd
, 3
rd
, 4
th
and 5
th
 best model by statistical model comparison criteria whereas the 
Exponential Model was ranked as the 6
th
 model in describing the data, although the Cox 
PH model provided the poorest fit due to some concern about its fit probably as a result 
of violence in the PH assumption. 
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5.2. Recommendations 
 Researchers who are interested in determining factors affecting survival of 
HIV/AIDS patients can explore the effects of some other factors such as Gender 
and Level of Education if they fit models based on purposely selected significant 
covariates. 
 Health workers should be cautious when a patient is in advanced clinical stages, 
old in age, relatively lower in weight, bedridden, opportunistically infected, TB 
positive, hazardous in behavior and has lower CD4 percent during ART initiation. 
 Concerned government authority/Health policy makers should arrange Nation 
wise trainings that can provide health workers and data clerks with uniform 
handling of information related to patients and law-abiding delivery of secured 
quality data for stakeholders at all level. 
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Appendix  
Summary Statistics of Continuous Covariates and Graphs of K-M Survivor 
Functions for Categorical Covariates 
Table7. 1: Summary Statistics for Continuous Covariates in the Dataset 
Variable Observations Mean Std. Dev. Min Max 
Age 3042 32.37881 11.12487 .03 99 
Weight 3042 46.03455 11.3793 3 89 
Household Size 3042 3.626233 1.560996 1 10 
Figure7. 1 (A-J): Graphs of K-M Survivor Functions for all Categorical Covariates 
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Figure7. 2 (A-G): Cumulative Hazard Plots for Testing PH Assumptions 
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Table7. 2: Test of PH Assumption by Using Schoenfeld Residuals 
Covariates Rho Chi2 DF Prob> Chi2 
WHO Clinical Stage (I as Reference)  1  
II 0.05811 1.74 1 0.1869 
III  0.07151 2.64 1 0.1042 
IV 0.05200 1.41 1 0.2357 
CD4 Percent (12-15% as Reference)  1  
16-28%  -0.04816 1.22 1 0.2700 
Above 28%   1  
TB Status (Negative as Reference)  1  
Positive  -0.01628 0.16 1 0.6899 
Functional Status (Working as Reference)  1  
Ambulatory  0.02268 0.29 1 0.5871 
Bedridden  0.06059 2.10 1 0.1473 
Opportunistic Infections (No as Reference)  1  
Yes -0.04282 0.85 1 0.3558 
Risk Behavior (No as Reference)  1  
Yes  -0.06201 2.16 1 0.1416 
Age  0.07981 4.05 1 0.0442 
Figure7. 3: Test of PH Assumption by Using Plot of Scaled Schoenfeld Residuals for 
Age against Rank of Survival Time 
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Figure7. 4 (A-Q): Index Plots of DFBETA Statistics for All Indicators in the Cox PH 
Model 
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Figure7. 5 (A-D): Quantile-Quantile Plots of Survival Time for Binary Covariates 
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Table: 7. 3: Parametric PH Models Analysis 
Covariates Exponential PH Weibull PH Gompertz PH 
  p 95%CI FOR     p 95%CI FOR
  
  p 95%CI FOR   
Age 0.01 0.02 0.00 0.02 0.01 0.02 0.00 0.02 0.01 0.02 0.00 0.02 
Gender 0.20 0.04 0.01 0.40         
FunctionalStatus 
1 0.32 0.00 0.12 0.52 0.25 0.01 0.05 0.45 0.26 0.01 0.07 0.46 
2 0.32 0.03 0.04 0.61 0.15 0.31 -0.14 0.43 0.14 0.35 -0.15 0.42 
Weight -0.01 0.02 -0.03 -0.00 -0.01 0.04 -0.02 -0.00 -0.01 0.03 -0.02 -0.00 
WHOClinicalStage 
1 1.12 0.13 -0.33 2.57 0.92 0.21 -0.52 2.37 0.93 0.21 -0.52 2.37 
2 1.71 0.02 0.31 3.10 1.25 0.08 -0.15 2.64 1.24 0.08 -0.16 2.63 
3 2.84 0.00 1.44 4.24 2.60 0.00 1.20 4.00 2.60 0.00 1.21 4.00 
CD4Percent 
2 -0.75 0.00 -1.09 -0.41 -0.67 0.00 -1.01 -0.33 -0.67 0.00 -1.01 -0.33 
3 -14.6 0.99 -1577.1 1548.0 -14.03 0.98 -1049.6 1021.6 -13.52 0.97 -810.9 783.85 
1.TBStatus 1.11 0.00 0.74 1.48 0.73 0.00 0.34 1.11 0.72 0.00 0.34 1.11 
Oportunistic
Infect~s 
    1.38 0.01 0.35 2.41 1.68 0.00 0.65 2.72 
1.RiskBehavior 1.57 0.00 0.70 2.44 0.99 0.02 0.16 1.82 1.03 0.02 0.19 1.86 
_cons -10.69 0.00 -12.34 -9.04 -43.13 0.00 -46.34 -39.93 -17.3 0.00 -19.4 -15.31 
/ln_p     2.08 0.00 2.02 2.15     
P     8.03  7.51 8.59     
1/p     0.12  0.12 0.13     
/gamma         0.08 0.00 0.08 0.09 
 
